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ABSTRACT OF THE DISSERTATION
A High-Throughput Screening Platform for In Vitro Elastic Fiber Production and the Mass
Transport Properties of the Elastic Fiber Compromised Arterial Wall
by
Austin Cocciolone
Doctor of Philosophy in Biomedical Engineering
Washington University in Saint Louis, May 2019
Research Advisor: Professor Jessica Wagenseil
Elastin comprises nearly 50% of the wall in large elastic arteries and has a broad variety of
physiological roles. As a structural extracellular matrix protein, elastin is responsible for the
reversible elasticity in large arties that dampens pulsatile flow and ultimately reduces the
workload on the heart. Structural compromise to the elastic fiber network is apparent in the
elastin genetic disorders, supravalvular aortic stenosis and autosomal dominant cutis laxa-1, and
acquired elastin disorders including hypertension, atherosclerosis, artery calcification,
aneurysms, diabetes, and obesity. All of these disorders lead to an increased incidence of
cardiovascular related death and the compromised elastic fiber network plays an important role
in the degeneration of cardiovascular function. Elastin also serves as an important biological
signal in both the development of the arterial vasculature and the progression of several of the
previously mentioned cardiovascular disorders. Elastin’s physiological role is often overlooked
in strategies being developed to treat these cardiovascular disorders. The work of this thesis has
focused on two areas in particular that elastic fibers have been underrepresented; the generation
of elastic fibers in vitro and the importance elastic fiber network on determining the mass
transport properties of the arterial wall.
ix
Tissue engineered arteries lack a proper elastic fiber network, in part because elastin content is
difficult to quantify and because inducing elastic fiber formation in vitro is challenging. We
developed a platform for measuring elastic fiber production in vitro. We used a competitive
ELISA for desmosine, an amino acid unique to elastic fibers, to detect elastic fiber production.
We made adjustments to the cell culture conditions of rat lung fibroblast cells to improve their
output of elastic fibers. We used this platform to perform a high-throughput screen on a small
molecule library to search for molecules that could induce elastic fiber production. We also used
our platform to screen the effect of minodixil and diazoxide on elastic fiber production as these
antihypertensive drugs have been shown by other researchers to induce elastin gene expression
but their effect on mature elastic fiber production was undetermined.
Drug delivery in pharmaceutical strategies for treating aneurysm formation, arterial stiffness, and
atherosclerosis is a rapidly developing area. However, current models of mass transport in the
arterial wall make numerous assumptions that either diminish the contribution of the elastic fiber
network or ignore it completely and there is a lack of empirical investigation on the transport
properties of the arterial wall. We hypothesized that the elastic fiber network serves to limit
transport across the wall. We developed ex vivo methods for measuring transmural advective
transport of solute and fluid in mouse carotid arteries at physiological pressure and axial stretch.
We investigated the effect of disrupting the elastic fiber network on arterial wall transport using
a genetic knockout of Fibulin-5 (Fbln5-/-) or treatment with elastase. Fibulin-5 is an important
director of elastic fiber assembly. Arteries from Fbln5-/- mice have a loose, non-continuous
elastic fiber network. The changes in transport properties of elastic fiber compromised arteries
xwe observed have important implications for the kinetics of biomolecules and pharmaceuticals in
arterial tissue following elastic fiber degradation due to aging or vascular disease.
1Chapter 1
Introduction
1.1 Motivation and Research Aims
Elastin is the main component of elastic fibers, an extracellular matrix (ECM) protein that
enables elastic extension and relaxation in large arteries. Elastin insufficiency or disorganization
and improper assembly, fragmentation, or biochemical modifications of elastic fibers change the
passive mechanical behavior of the large arteries and ultimately disrupt cardiovascular dynamics
in multiple ways. Both genetic and acquired cardiovascular diseases are associated with elastin
and elastic fiber defects and have an increased incidence of cardiovascular related death.
Mutations in the elastin gene may cause either supravalvular aortic stenosis (SVAS) or
autosomal dominant cutis laxa-1 (ADCL1). Acquired cardiovascular diseases including arterial
stiffness and hypertension, diabetes, obesity, aneurysms, atherosclerosis, and arterial
calcification are associated with elastic fiber degradation or biochemical modification. This
degradation initiates a destructive arterial remodeling cascade that is difficult to stop and may be
impossible to reverse.
Elastin gene expression and elastic fiber assembly occur primarily during development and are
essentially turned off afterwards. Although elastin’s resiliency provides it with a long half-life of
70 years, the lack of elastic fiber matrix turnover makes it susceptible to fragmentation and
degradation accumulation. Preserving the elastic fiber matrix or promoting de novo elastic fiber
production through pharmaceutical intervention and tissue-engineered arteries are potential
2strategies for intervening on elastinopathy progression. Crucial to the development of these
interventions is an improved understanding of elastic fiber assembly and degradation.
Through the investigations presented in this dissertation, we aimed to advance the knowledge of
elastic fiber assembly and degradation. We have developed a platform for screening molecules
for activity in promoting elastic fiber production. We used this platform to investigation factors
that have demonstrated elastin gene upregulation by other researchers and also performed a high-
throughput screen on a library of small molecules. Additionally we have investigated the effects
of elastic fiber degradation on the transport of molecules across the arterial wall by performing a
series of mass transport studies on elastic fiber compromised tissues.
1.2 Summary of Chapters
Chapter 2 of this dissertation broadly reviews the physiological role of elastin and the animal
models which have largely enabled the current state of knowledge on elastin. We summarize the
multi-step process of elastic fiber assembly and the challenges and recent advances in generating
functional elastic fibers in vitro. We discuss the unique mechanical properties of large elastin
containing arteries that are dependent upon elastic fiber integrity and amount. We review the
genetic disorders supravalvular aortic stenosis (SVAS) and autosomal dominant cutis laxa-1
(ADCL1), which are caused by mutations in the elastin gene. Additionally we review
hypertension and arterial stiffness, diabetes, obesity, atherosclerosis, calcification, and
aneurysms and dissections which are acquired diseases associated with elastic fiber defects.
3In chapter 3 we present our work towards the development of a screening platform capable of
identifying compounds from a molecular library that induce increased elastic fiber production in
vitro. We chose a competitive ELISA for the determination of elastic fiber content and we report
our cell culture conditions which demonstrate elastic fiber producing capability. We used our
screening platform to look for potential candidate factors to serve as positive controls for elastic
fiber production. We then performed a high-throughput screen on a library of nearly 1600 small
molecules and state the results of the primary and secondary screen.
In chapter 4 we investigate the mass transport properties of mouse carotid arteries with
compromised elastic fibers. This research was enabled by two different animal models; the
Fibulin-5 genetic knockout (Fbln5-/-) which have an improperly assembled elastic fiber matrix in
the arterial wall and an elastase treatment we developed to degrade the arterial elastic fiber
matrix. We developed experiments for the measures of hydraulic conductance, advective solute
transport, and tissue uptake of solute for these elastic fiber compromised tissues and their
comparison to intact tissues.
Chapter 5 is a summary of the major conclusions of this dissertation and their significance in
furthering current knowledge and offer potential future directions that may build upon these
discoveries.
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Chapter 2 
 
Elastin, Arterial Mechanics, and Cardiovascular Disease1 
 
 
2.1Elastin 
2.1.1 Elastin characterization 
Elastin is an elastic protein polymer that is highly resilient due to extensive post-translational 
crosslinking of the monomeric precursor, tropoelastin. Reviews focusing on tropoelastin and/or 
elastin have been written by Vrhovski and Weiss (1) and Kozel et al. (2). Due to the numerous 
crosslinks at lysine residues and having a composition of nearly 75% hydrophobic residues, 
elastin is extremely hydrophobic (1). The precursor, tropoelastin, is a 70 kDa protein transcribed 
from a single elastin gene in the mammalian genome (3-5). The human elastin gene is 45 kb, 
located on chromosome 7, and contains 34 exons of which each exon encodes either a 
hydrophobic or crosslinking domain in an alternating pattern (6-9) (Figure 2.1). Elastin is only 
present in vertebrate animals and there is extensive homology amongst human, chick, bovine, 
and rat species at the nucleic and amino acid levels (1). During an organism’s lifespan, elastin 
gene expression and protein synthesis occur within a narrow timeframe initiating late in 
embryonic development and terminating in adolescence with essentially no de novo elastin 
production throughout adult life of the animal (10-17). The narrow timeframe of elastin 
expression and synthesis is unusual for an ECM component, as generally ECM production is 
dynamic throughout the organism’s lifespan. Because of elastin’s resilience and a half-life of 
                                                          
1 Reprinted with additional changes from Cocciolone AJ, Hawes JZ, Staiculescu MC, Johnson EO, Murshed M, 
Wagenseil JE. Elastin, arterial mechanics, and cardiovascular disease.  Am J Physiol Heart Circ Physiol. 2018 Aug 
1;315(2):H189-H205 with permission from the American Physiological Society © 2018. 
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nearly 70 years, the limited time period of expression and synthesis is sufficient for the protein to 
last a lifetime in most species (18, 19). 
 
Figure 2.1 - Domain structure of the human elastin gene. Alternating hydrophobic and crosslinking domains 
are generally transcribed by individual exons. The locations of 64 unique polymorphisms (Human Gene 
Mutation Database, www.hgmd.cf.ac.uk) associated with either SVAS (red, 49 mutations not including large 
deletions) or ADCL1 (blue, 15 mutations) are indicated. 
2.1.2 Regulation of tropoelastin expression 
Immunohistochemistry studies in developing chicken lung (20) and aorta (21) show that 
tropoelastin expression correlates with smooth muscle differentiation markers and suggest that 
transcription of elastin is developmentally regulated. Tropoelastin mRNA levels are decreased  
in adult compared to neonatal rat lungs, but tropoelastin pre-mRNA levels are similar, suggesting 
that post-transcriptional regulation turns off tropoelastin expression in adulthood (22). An 
element in the open reading frame specifically binds a cytosolic protein that destabilizes 
tropoelastin mRNA. Binding affinity increases in adult compared to neonatal lung fibroblast 
cells, mediating rapid tropoelastin mRNA decay, and decreasing overall mRNA levels. Binding 
affinity is decreased by TGF-ß1 (23), which stimulates tropoelastin expression in human fetal 
lung fibroblasts by stabilizing its mRNA (24). Active Smads and de novo tropoelastin expression 
are required for TGF-ß1 mediated tropoelastin mRNA stabilization in cell culture (25). TGF-ß1 
immunoreactivity is present at the sites of arterial elastin expression as detected by in situ 
hybridization, supporting a role for TGF-ß1 regulation of tropoelastin expression in vivo (26). 
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TGF-ß1 may additionally regulate tropoelastin expression through interactions with the promoter 
region in a tissue-specific manner (27). IGF-1, vitamin D, and IL-1ß also modulate tropoelastin 
expression, at either the promoter level or through increased mRNA stability (1). Cytokine 
regulation of tropoelastin expression has been reviewed by Sproul and Argraves (28). 
 
2.1.3 Coacervation and crosslinking 
In the arterial wall, tropoelastin is primarily produced from vascular smooth muscle cells 
(VSMCs) in the media (21, 29), although it can also be produced by endothelial cells (ECs) in 
the intima (30, 31) and fibroblasts in the adventitia (32, 33). After secretion to the extracellular 
space, tropoelastin simultaneously undergoes coacervation and crosslinking. Crosslinking is 
facilitated by enzymes from the lysyl oxidase family, in particular lysyl oxidase (LOX) and lysyl 
oxidase like-1 (LOXL-1). The role of LOX in elastic fiber assembly has been reviewed by 
Lucero and Kagan (34). Coacervation is a reversible and thermodynamically driven self-
assembly of tropoelastin into globular aggregates that occurs spontaneously at physiological 
temperatures and is a consequence of the numerous hydrophobic regions in tropoelastin (35-40). 
LOX activity appears to depend on coacervation, as LOX demonstrates higher affinity for 
insoluble, coacervated tropoelastin and is less effective at crosslinking tropoelastin at 
temperatures below the threshold for spontaneous coacervation (41, 42). While accepted that 
coacervation is a critical step to crosslinking, it is unclear whether this is due to induced 
conformational changes in tropoelastin or to tropoelastin sequestering (1, 42, 43). 
 
Through the activity of LOX, an oxidative deamination reaction converts many lysine residues 
into allysine (44). It is suspected that the presence of an aromatic residue adjacent to and on the 
C-terminal end of lysine sterically inhibits LOX activity, preserving several lysine residues for 
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downstream reactions in the crosslinking process (45). Following side chain oxidation, a 
sequence of spontaneous condensation reactions occurs between the newly formed allysine 
residues and unreacted lysine residues to form covalent crosslinks called desmosine and 
isodesmosine between tropoelastin units. Desmosine and isodesmosine are unique to elastin and 
serve as a basis for quantification of elastin amounts in tissues (46).  
 
2.1.4 Elastic fiber assembly 
Elastin forms the core of elastic fibers and is the most abundant component of the mature 
structure. The other major component is a scaffold of microfibrils, which are composed mostly 
of fibrillin-1 and -2 (47, 48). Elastic fiber assembly involves nearly 30 different proteins that are 
tightly coordinated spatially and temporally (43). The function of only a handful of these 
associated proteins is understood and elucidation of the function of others is an active area of 
investigation. Reviews focusing on elastic fiber assembly have been written by Kielty et al. (43), 
Wagenseil and Mecham (49), and Yanagisawa and Davis (50). Spontaneous tropoelastin 
coacervation and the crosslinking catalyzed by LOX at the cell surface initiates the assembly 
process. There is evidence that some of the associated assembly proteins, namely fibulin-4 
and/or -5 (FBLN4, -5), serve to modulate the size and conformation of the developing elastin 
aggregates (51). These elastin aggregates are then shuttled to the microfibrils that are anchored to 
the cell surface through integrins. Finally, further crosslinking occurs, again through LOX, to 
develop the mature elastic fiber which provides elasticity to the large, elastic arteries. 
 
2.1.5 Elastolytic enzymes 
Proteases capable of degrading elastin or elastic fibers are known as elastases. In total, 12 
elastases have been identified, however they are non-specific to elastin. Neutrophil elastase (Ela-
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2), cathepsin G (CatG) and proteinase-3 (Pr-3) are serine-class proteases that may have a 
stronger affinity for tropoelastin than crosslinked elastin. They have been found in 
atherosclerotic plaques, are secreted from neutrophils, and likely contribute to atherosclerosis 
progression (52). Ela-2 and CatG are also secreted from VSMCs in the pulmonary artery (53). 
Four matrix metalloproteinases (MMP-2, -7, -9, and -12) have elastolytic activity. All four 
MMPs are secreted by macrophages, linking elastic fiber degradation and inflammation. MMP-2 
and -9 are also produced by VSMCs and are able to activate latent TGF-ß (54). There are three 
levels of post-translational regulation of MMP activity. MMPs are initially secreted as inactive 
pro-MMPs that require proteolytic cleavage of the propeptide; activity is also turned on by the 
deactivation of a cysteine switch; and MMPs are regulated by specialized inhibitors called tissue 
inhibitors of matrix metalloproteinases (TIMPs) (55). Another four elastases, also secreted by 
macrophages, belong to the cysteine class: cathepsin L, S, K, and V (CatL, -S, -K, and -V). CatL, 
-S, and -K are also expressed by VSMCs (52). Pepsin A is the final known elastase, but as a 
digestive enzyme released in the stomach it is unlikely to play a role in vascular remodeling.  
 
2.2 Arterial Mechanics 
2.2.1 Arterial wall structure  
The structure of the arterial wall is divided into three layers: intima, media, and adventitia. The 
intima is a single layer of ECs directly adjacent to the arterial lumen that sits on a basement 
membrane constructed of type IV collagen, laminin, and proteoglycans (56). The middle and 
largest layer, the media, is further sublayered into lamellar units defined by fenestrated sheets of 
elastic fibers (Figure 2.2), or elastic laminae. These laminae are separated by a region composed 
of VSMCs, thin elastic fibers, collagen (mostly types I and III), and proteoglycans (57-60). An 
internal elastic lamina separates the media from the intima. Elastic fibers and collagen 
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interconnect the elastic laminae forming a continuous network with three-dimensional helical 
structure in which the fibers are oriented in a near circumferential direction (58). The number of 
lamellar units decreases along the arterial tree with larger elastic arteries, such as the descending 
thoracic aorta, having approximately 60 units in humans (61) and muscular arteries closer to the 
periphery having fewer than three units. The number of lamellar units scales with physiologic 
pressure and arterial size across mammalian species, providing a constant wall tension/lamellar 
unit (62). Cross-sections of a large and small artery from a mouse, demonstrating the number and 
organization of elastic laminae in the wall, are shown in Figure 2.3. An external elastic lamina 
exists between the media and the outermost layer, the adventitia, in large arteries but is absent in 
the smallest muscular arteries. The adventitia contains fibroblasts, fibrocytes, and a collagen-rich 
matrix. Large ateries in large animals contain a vasa vasorum in the adventitia to supply blood to 
the outer wall cells that are too far from the arterial lumen for diffusion of oxygen and nutrients 
across the wall. 
 
Figure 2.2 - Structure of the elastin network in arterial elastic laminae. En face images of elastin in a WT 
mouse ascending aorta obtained using nonlinear fluorescence microscopy (63). Dense, fenestrated (arrows) 
elastin network is observed in elastic laminae near the inner media (left). The network appears more fibrous 
toward the outer media (right). Circumferential direction is horizontal; axial direction is vertical. Scale bars 
= 20 μm. 
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Figure 2.3 - Organization of the elastic laminae 
in large and small arteries. Cross-sections of a 
mouse descending aorta (A) and mesenteric 
artery (B) stained for elastin (red) and cell 
nuclei (blue) (64). The descending aorta has 
multiple layers of elastic laminae. The 
mesenteric artery has an internal elastic 
lamina at the luminal surface and a thin 
external elastic lamina at the adventitial 
surface. The lumen is marked with an “L”. 
Scale bars = 20 μm. 
 
2.2.2 The windkessel effect 
Elastin is only present in vertebrate animals with a closed circulatory system and pulsatile 
pressure and flow (65). The amount of elastin is highest in the large, elastic arteries closest to the 
heart and decreases as one moves distally in the cardiovascular system (66). Elastic fibers 
provide reversible elasticity to the large, elastic arteries. This allows the aorta to deform 
elastically under an applied hemodynamic load, with no permanent deformation and no energy 
dissipation when the load is removed. Stephen Hales in 1733 recognized the importance of 
arterial elasticity in cardiovascular function and Otto Frank in 1895 formalized Hales’ ideas into 
a mathematical model of the Windkessel effect (67). A Windkessel is an air chamber that was 
used in fire engines during the 18th century to convert pulsatile pumping into a constant flow of 
water. In the cardiovascular system, the Windkessel effect dampens the pulsatile flow from the 
left ventricle (LV), so that the distal vasculature receives almost constant perfusion. Blood 
ejected from the LV during systole distends the aortic wall and during diastole the aorta 
reversibly returns to its original configuration. The strain energy stored during systolic 
deformation is returned as work to further pump blood downstream during diastole. If the 
Windkessel effect is compromised, for example by increased arterial stiffness in aged or diseased 
arteries, the microvasculature of downstream organs, especially in the brain and kidney, can be 
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damaged (68). Furthermore, the Windkessel effect reduces cardiac afterload and perfuses the 
coronary arteries during diastole, hence cardiac function can deteriorate when the Windkessel 
effect is compromised (69). 
 
The Windkessel effect can be compromised through genetic or acquired elastinopathies that alter 
elasticity of the arterial wall. Elasticity can be altered by increasing wall stiffness or increasing 
energy dissipation so that less stored strain energy is available to do work on circulating blood. 
Increased wall stiffness also increases the pulse wave velocity (PWV) of traveling pressure 
waves in the cardiovascular system. Reflected waves from arterial branch points normally 
augment diastolic pressure, but increased PWV causes the reflected waves to return earlier in the 
cardiac cycle and augment systolic blood pressure, leading to systolic hypertension, decreased 
diastolic perfusion, and increased pulse pressure which can further damage downstream organs 
(70).  
 
2.2.3 Arterial stiffness and passive mechanical behavior 
Arterial stiffness is a structural mechanical property that depends on the material properties and 
geometry of the arterial wall. Common measurements of stiffness include Peterson’s modulus, 
distensibility, and PWV (71) and almost always refer to deformation and loading in the 
circumferential direction. We will call these measurements “structural stiffness” values. 
Peterson’s modulus and distensibility can be measured in vivo or in vitro, while PWV is usually 
measured in vivo. PWV can be determined simply and reproducibly in the clinic by recording the 
time it takes for a blood pressure pulse wave to travel a specified distance in the arterial tree 
(usually from the carotid to the femoral artery) (72). PWV is a measure of structural stiffness 
because the value is related to the Young’s modulus of the arterial wall (a material property), the 
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wall thickness, arterial diameter, and the density of blood according to the Moens-Korteweg 
equation (71). The derivation of the Moens-Korteweg equation assumes that the aorta is a perfect 
cylinder with no tapering or branches, made up of a linear elastic, isotropic material that 
experiences small deformations during the cardiac cycle, none of which are precisely true. While 
PWV is a useful measure of structural arterial stiffness, the assumptions accompanying its use 
must be kept in mind. 
 
Arterial wall material properties are nonlinear and vary with the direction of deformation and 
loading (i.e. circumferential vs. axial), hence they cannot be quantified by a single measurement, 
such as the Young’s modulus in the Moens-Korteweg equation. However, estimates of arterial 
material properties can be obtained by linearizing the mechanical behavior within a given 
deformation or loading range in a specified direction to provide an incremental Young’s modulus 
for comparison across samples (71). Material stiffness values can also be obtained by fitting 
constitutive models to detailed in vitro mechanical testing data and calculating derivatives of the 
conjugate stress and strain measurements (73). Fitting constitutive models allows comparison of 
material behavior and stored strain energy for any loading condition in any direction, but 
requires multiple experimental protocols for each sample and is dependent on the suitability of 
the chosen constitutive equation.  
 
The passive mechanical behavior of large, elastic arteries is determined mostly by the amount 
and organization of elastic fibers and collagen fibers in the wall. VSMCs contribute to arterial 
mechanics through active contraction or relaxation and by producing the surrounding ECM 
proteins, but they do not contribute substantially to the passive mechanical behavior (74). 
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Although there is only one elastin protein, there are multiple collagen proteins. The most 
abundant arterial collagens are types I and III, with lesser amounts of IV, V, and VI. The 
amounts and transmural organization of collagen types depend on location in the cardiovascular 
tree (60). Elastic arteries show nonlinear behavior with maximum distensibililty near physiologic 
pressures and reduced distensibility at high pressures (75), presumably to protect the cells and 
protein components from irreversible damage due to excessive deformation. Selective digestion 
of elastic fibers or collagen fibers with proteases indicates that the resistance to stretch in elastic 
arteries at low pressures is due to elastic fibers, while the resistance to stretch at high pressures is 
due to collagen fibers (76-79). Experiments on the aorta from mice lacking elastin (Eln-/-) 
demonstrate a reduction in the circumferential material stiffness at low pressure, consistent with 
the observed role of elastic fibers in protease experiments (80). However, experiments on arteries 
from elastin haploinsufficient mice (Eln+/-) with 50-60% of normal elastin levels show similar 
circumferential stress-stretch behavior to wild-type (WT) mice (Figure 2.4), which has been 
attributed to remodeling of the cardiovascular system during development and maturation (81, 
82). 
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Figure 2.4 - Effects of elastin amounts on arterial mechanical behavior. Representative pressure-outer 
diameter (A, B) and circumferential Cauchy stress-stretch ratio (C, D) curves (81) for the ascending aorta 
(ASC) (A, C) and left common carotid (LCC) (B, D) from WT (100% elastin), Eln+/- (50-60% elastin), and 
hBAC-mNull (30-40% elastin) mice. Decreased elastin amounts shift the pressure-diameter behavior for both 
artery locations, but the difference between Eln+/- and hBAC-mNull pressure-diameter behavior for the LCC 
is negligible. For both artery locations, the stress-stretch behavior is similar between WT and Eln+/- mice, but 
becomes more nonlinear at lower stretch ratios for hBAC-mNull mice. The data highlight the importance of 
examining structural (pressure-diameter) and material (stress-stretch) mechanical behavior, as well as 
differences between artery locations in the structural response to reduced elastin amounts. The results 
suggest that mouse arteries can remodel to maintain WT material behavior when elastin amounts are 50-60% 
of normal, but cannot fully remodel and adapt the material behavior when elastin amounts are 30-40% of 
normal. 
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Remodeling of the arterial wall in response to genetic or acquired elastinopathies is important for 
determining the physiologic mechanical behavior. Production and reorganization of collagens 
(83) or other ECM components, such as proteoglycans (84), are often observed in response to 
defects in or degradation of the elastic fibers. Additional collagen deposition or a shift in the 
ratio of different types of collagens in the wall may increase stiffness of the wall, affect the 
Windkessel function, and the strain energy storage capacity (85). Additional proteoglycans may 
pool in the wall and provide a catalyst for arterial dissections (86). 
 
2.2.4 Energy storage and return 
Because elastin is a highly resilient protein, it allows the wall of the large arteries to deform with 
little energy loss on loading and unloading. Energy loss is small, but finite at 15-20%, and this 
value appears to be consistent across various species (87). Energy loss is attributed to viscous 
losses from VSMCs (88) or proteoglycans (89). The relative contributions of different 
components to the viscoelastic behavior of arteries have been determined using protease 
digestion in a similar manner to the elastic contributions for different pressure ranges. Recent 
experiments on newborn mouse aortae lacking elastin (Eln-/-), lysyl oxidase (Lox-/-), or fibulin-4 
(Fbln4-/-) show that properly assembled and crosslinked elastic fibers are necessary for low 
energy loss (80). Many investigations do not include energy loss in mechanical studies on large 
elastic arteries, but this may be an important consideration in diseases with highly fragmented 
elastic fibers.  
 
2.3 Elastin as a Signaling Molecule 
2.3.1 Tropoelastin 
While we have focused so far on the mechanical effects of structural changes in elastic fibers, 
elastin and its degradation products have chemical signaling effects as well. For example, soluble 
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tropoelastin can regulate cell phenotype. Adding tropoelastin to the culture media of VSMCs 
from Eln-/- mice inhibits proliferation (90) and increases stiffness as measured by atomic force 
microscopy (AFM) (91). Karnik et al. showed that a specific domain within tropoelastin, 
VGVAPG, induces actin polymerization in VSMCs through a G protein coupled pathway (92). 
The VGVAPG peptide is a potent chemoattractant for VSMCs (92), fibroblasts, and monocytes 
(93). Sites have been identified at the C-terminus and central region of tropoelastin that mediate 
binding to αVß3 and αVß5 integrins, which are involved in numerous signaling pathways (94, 95). 
Non-integrin mediated interaction between tropoelastin and the cell membrane has also been 
identified through the binding of fractionated tropoelastin to heparin sulfated proteoglycans (96). 
Tropoelastin expression is detectable in adult human aorta at decreasing levels with aging (97), 
implying that reduced tropoelastin, as well as degradation and modification of existing elastic 
fibers may modulate age-related changes in the arterial wall.   
 
2.3.2 Elastin-derived peptides 
Elastic fibers can be degraded and fragmented by mechanical fatigue, calcification, glycation, 
lipid peroxidation, and protease digestion (98). The resulting elastin-derived peptides (EDPs) are 
bioactive and retain the VGVAPG peptide sequence found in tropoelastin, rendering similar 
signaling capability. EDP levels in the blood are increased in humans with obliterative 
arteriosclerosis of the legs, type IIb hyperlipidemia, hypertension, diabetes, and ischemic heart 
disease (99). Whether the increased levels of EDPs are a cause or consequence of the disease is 
unknown. Recent studies in mice suggest that while elastic fiber fragmentation may be secondary 
to the genetic or acquired disease, circulating EDPs contribute to further disease progression. 
Chronic doses of EDPs, as well as VGVAPG peptides, increase the size of atherosclerotic 
plaques at the aortic root in two different atherosclerosis susceptible mouse models  (100). EDPs 
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are capable of binding the lactose-insensitive receptor found on the surface of macrophages, 
implicating a role for EDPs in macrophage migration in inflammation and atherosclerosis 
progression (101). A single dose of EDPs, as well as VGVAPG peptides, causes hyperglycemia 
in mice (93). Rat aortic VSMCs incubated with EDPs show increased expression of typical bone 
proteins, which may contribute to arterial calcification (102). An antibody to VGVAPG blocks 
EDP signaling to inflammatory cells and protects against elastase induced emphysema in mice 
(103). The VGVAPG antibody also reduces aortic elastic fiber fragmentation, macrophage 
infiltration, and TGF-ß1 activity in a mouse model of aortic aneurysm due to reduced fibrillin-1 
levels (104). Finally, VGVAPG sequence-carrying EDPs have been shown to interact with the 
galectin-3 receptor, which is involved in melanoma chemotaxis and expression of MMP-2 and -3 
(105). A review summarizing the effects of elastin degradation and EDPs in cardiovascular aging 
and disease has been written by Duca et al. (98). 
 
2.3.3 Elastin receptor complex 
Many of the chemical signaling effects of tropoelastin and/or EDPs are thought to be mediated 
by the elastin receptor complex (ERC) (52). The ERC is composed of two membrane-bound 
subunits, protective protein/cathepsin A (PPCA) and neuraminidase-1 (Neu-1), plus the elastin 
binding protein (EBP). EBP (also known as S-Gal) is a splice variant of lysosomal ß-
galactosidase that retains the ability to bind galactosugars, but has lost enzymatic activity. In 
addition, the splice variant has a 32-peptide sequence capable of binding tropoelastin (106). In 
elastogenesis, EBP is thought to be responsible for shuttling tropoelastin to the cell surface and 
antagonistic interaction between EBP and galactose or lactose may release tropoelastin to the 
extracellular space (107). Neu-1 appears to control signal transduction by ERC through the 
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catalytic conversion of ganglioside to lactosylceramide (108). Downstream signaling of the ERC 
diverges depending on cell type but reconvenes at the activation of ERK1/2 (98). 
 
2.3.4 TGF-ß sequestration 
TGF-ß is secreted from cells in the form of a large latent complex (LLC) that includes a latency 
associated peptide (LAP) and a latent TGF-ß binding protein (LTBP). LTBP localizes latent 
TGF-ß to the ECM. LTBP1 and -3 bind well to all three TGF-ß isoforms (109). LTBP1 has 
specific interactions with fibrillin-1 microfibrils (110). Although direct interactions of LTBP3 
with fibrillin-1 have not been shown, LTBP3 protein is reduced in the aorta of fibrillin-1 
knockout (Fbln1-/-) mice (111). In the early stages of elastic fiber assembly, microfibrils are 
abundant and there is little elastin. Throughout late embryonic development and early 
maturation, elastin synthesis increases and eventually obscures the microfibrils (112). It is 
possible that elastin accumulation indirectly regulates TGF-ß availability by modulating LLC 
binding to the microfibrils. TGF-ß1 immunoreactivity and tropoelastin expression co-localize in 
developing rat aorta and decrease with age (26). This has been interpreted as evidence of TGF-ß1 
regulated expression of tropoelastin in vivo, but it could also be interpreted as tropoelastin 
regulated availability of TGF-ß1 as elastin accumulates on the microfibrils. TGF-ß1 signaling is 
altered when arterial elastic fibers are not assembled properly and through proteolytic cleavage 
of elastic fiber associated proteins, indicating bidirectional effects between TGF-ß1 activity and 
elastic fiber integrity (113). Elastinopathies that alter elastin amounts or elastic fiber integrity 
may then affect TGF-ß activity (114).  
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2.4 Cardiovascular Disease 
Several genetic and acquired cardiovascular diseases are associated with elastin and elastic fiber 
defects. The defects include altered amounts of elastin, and improper assembly, fragmentation, 
and modification of elastic fibers. Additional reviews on cardiovascular diseases associated with 
elastin or elastic fiber defects have been written by Baldwin et al. (115) and Milewicz et al. 
(116).  
 
2.4.1 Genetic elastinopathies 
Supravalvular aortic stenosis  
Supravalvular aortic stenosis (SVAS, OMIM #185500) is a rare (~1:20,000 births) congenital 
obstruction of the LV outflow tract. The defining defect is a lesion in the aorta at the sinotubular 
junction (STJ) as a result of VSMC hypertrophy, increased collagen, and reduced/disorganized 
elastic fibers in the medial layer (117, 118). Often there are additional morphological defects in 
other elastic arteries, but the arteries affected and severity of the defects is patient specific. There 
are three forms of SVAS: autosomal-dominant familial, sporadic, and Williams-Beuren 
syndrome (WBS, OMIM #194050) associated. The genetic origin defines the form of SVAS. 
Familial and sporadic SVAS arise from loss-of-function mutations to the elastin gene that are 
either inherited or de novo, respectively. A variety of mutations have been reported, including 
translocations, partial deletions, and point mutations (Figure 2.1), often resulting in a truncated 
elastin protein. In WBS associated SVAS the entire elastin gene, along with 25 - 27 other genes, 
is encompassed in a large deletion on chromosome 7 (119). In all cases, one functional elastin 
gene remains and sporadic mutations are more common than inherited mutations (120). 
 
SVAS can present as one of two different types. Type I (discrete) is defined by a localized 
narrowing at the STJ. Type II (diffuse) shows uniform narrowing beginning at the STJ and 
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extending as far as the aortic arch or even the descending aorta (121). The ratio of Type I:Type II 
incidence is approximately 7:3 (122). Due to the rarity of SVAS, data correlating Type I or II to 
specific elastin mutations is not available (123). In addition to the primary STJ lesion, vascular 
defects occur in other arteries. Often the aortic valve leaflets are hypertrophic, resulting in partial 
fusion of the leaflets to the STJ (124). 39% of SVAS patients have bicuspid aortic valve (123). 
Pulmonary artery stenosis is present in 83% of SVAS patients (122, 125). Lesions in the right-
ventricular outflow tract are also common (123). Coronary arteries can exhibit fibrodysplasia and 
may have stenotic lesions (126). Because coronaries are muscular arteries, it is unclear whether 
the lesions are a direct result of the elastinopathy or are a secondary pathology.  
 
Hypertension is common in WBS patients even at early ages (127) and may be linked to 
increased arterial structural stiffness due to reduced elastin amounts. Kozel et al. measured PWV 
in 77 patients with WBS and found an increase versus healthy controls. However, the increased 
PWV was independent of whether or not the patient was hypertensive (128). While hypertension 
and increases in arterial structural stiffness generally develop coincidentally in acquired 
cardiovascular disease, their dissociation in WBS may indicate that reduced elastin amounts are a 
common causal factor. SVAS patients have an increased risk of sudden cardiac death (SCD), 
with WBS patients having the highest risk (122). The most common cause of SCD is myocardial 
ischemia, likely resulting from coronary obstruction and LV hypertrophy (129). Ischemia could 
also be caused by reduced coronary perfusion during diastole due to a compromised Windkessel 
effect. Compromised arterial Windkessel function would also increase cardiac afterload and 
could contribute to LV hypertrophy. 
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Autosomal dominant cutis laxa-1 
Autosomal dominant cutis laxa-1 (ADCL1, OMIM #123700) is a rare connective tissue disorder 
in which the skin is loose, hyperextensible, and has redundant folds. Patients may have 
cardiovascular pathologies including bicuspid aortic valve, dilation of the aorta or pulmonary 
artery, and pulmonary emphysema (130).The majority of reported ADCL1 cases have a frame 
shift mutation within the last five exons of the ELN gene (Figure 2.1). The result of the 
frameshift is usually an elongation of the tropoelastin protein that is believed to form larger 
aggregates during coacervation and impair the ability of elastin to bind to the microfibrillar 
scaffold during elastic fiber assembly. Callewaert et al. demonstrated impaired tropoelastin 
deposition onto microfibrils, increased TGF-ß signaling, and indications of endoplasmic 
reticulum stress in cultured fibroblasts from ADCL1 patients (131). In nearly 50% of ADCL1 
cases, aneurysms are present in the aortic root, aortic arch, or pulmonary artery. Aneurysm 
development is likely a combined result of reduced elastic fiber synthesis and increased 
susceptibility to elastic fiber degradation (132). 
 
2.4.2 Mouse models of genetic elastinopathies 
Targeted deletion of the elastin gene in mice was first reported by Li et al. in 1998 (133). Eln-/- 
mice represent an extreme elastinopathy and provide insight into the role of elastin in arterial 
mechanics, VSMC phenotype modulation, and cardiovascular disease. The same year, Li et al. 
showed that elastin haploinsufficient (Eln+/-) mice demonstrate some of the cardiovascular 
phenotypes observed in SVAS patients, such as increased arterial structural stiffness and an 
increased number of arterial lamellar units, but do not have the local aortic lesions observed in 
SVAS (134). A mouse model of WBS with a large deletion that includes the elastin gene (135) 
has a similar cardiovascular phenotype to Eln+/- mice (136). Eln+/- mice have been used to study 
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cardiovascular effects of reduced elastin amounts and the associated increases in arterial 
structural stiffness. 
 
Due to the insertion of a short exon after exon 4 in the mouse and the loss of two exons (34 and 
35) in the human during primate evolution, the mouse Eln gene has 37 exons, while the human 
ELN gene has 34 exons (137). The human ELN gene also shows unique alternative splicing 
patterns (138). To create a mouse model to study ELN mutations in human disease, Hirano et al. 
expressed the human elastin gene in a bacterial artificial chromosome (BAC) in Eln-/- mice (139). 
These hBAC-mNull mice only express human elastin and have total elastin amounts at 30 – 40% 
of normal (139). hBAC-mNull mice also show VSMC hypertrophy and aortic luminal narrowing 
representative of SVAS lesions (140). Sugitani et al. engineered a single base deletion associated 
with ADCL1 within the ELN gene in a BAC and expressed it in mice (141). The mutant elastin 
was incorporated into elastic fibers in the mouse skin and lung and compromised tissue function. 
The mutant elastin was incorporated at low levels into the mouse aorta and did not affect tissue 
function. The results show tissue specific differences in elastic fiber assembly and highlight the 
utility of “humanized” mice for studying human disease (141). 
 
2.4.3 Effects of graded elastin amounts in mice  
Eln-/-, Eln+/-, and hBAC-mNull mice allow investigation of how graded amounts of elastin affect 
cardiovascular function. They are relevant for determining threshold amounts of elastin 
necessary for restoring cardiovascular function in genetic and acquired elastinopathies, as well as 
in tissue-engineered arteries. Each mouse model is discussed in additional detail below. 
Comparisons of arterial mechanics, wall structure, and morphology for WT mice with 100% of 
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normal elastin amounts, Eln+/- mice with 50 – 60% of normal elastin amounts, and hBAC-mNull 
mice with 30 – 40% of normal elastin amounts are shown in Figs. 2.4, 2.5, and 2.6, respectively. 
 
Figure 2.5 - Effects of elastin amounts on arterial wall structure and composition. Histological sections (64) of 
the left common carotid artery from WT mice with 100% elastin (A, D, G), Eln+/- mice with 50-60% elastin 
(B, E, H), and hBAC-mNull mice with 30-40% elastin (C, F, I). Verhoeff-Van Gieson (VVG) stained sections 
(A - C) show black elastic laminae, brown muscle tissue, and pink collagen. The elastic laminae are thinner, 
more numerous, and have more diffuse staining as elastin amounts decrease. Picrosirius red (PSR) stained 
sections (D - F) show collagen fibers in red and other material in yellow. In WT arteries, red collagen clearly 
outlines the yellow elastic laminae. In Eln+/- and hBAC-mNull arteries, the collagen staining overlaps with the 
elastic laminae. H&E stained sections (G - I) show cell nuclei in purple and other material in pink. Scale bars 
= 20 μm. 
 
0% elastin 
Eln-/- mice die within a few days of birth due to VSMC overproliferation in the aortic wall 
leading to luminal occlusion that is similar to the aortic root lesion observed in SVAS (133). Eln-
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/- mice have normal blood pressure and aortic structural stiffness at embryonic day 18 (142), but 
high blood pressure and increased aortic structural stiffness at birth (143). Aortae from Eln-/- 
mice have decreased aortic material stiffness compared to WT in the low pressure range, but 
similar aortic material stiffness to WT in the high pressure range (80). VSMCs from Eln-/- mice 
have higher proliferation rates (90) and lower material stiffness values (91) and these phenotypes 
can be partially reversed by the addition of tropoelastin to the cell culture medium. Treatment 
with mTOR inhibitor rapamycin decreases VSMC overproliferation in Eln-/- mice, but does not 
extend their lifespan (144). Integrin ß3 expression is upregulated in Eln-/- aorta and genetically 
reducing integrin ß3 dosage extends the lifespan of Eln-/- mice by approximately two days (145). 
Pharmacologic inhibition of ß3 with cilengitide reduces VSMC overproliferation in the Eln-/- 
aorta and may be a novel treatment to prevent SVAS (145). 
 
Figure 2.6 - Effects of elastin amounts on arterial morphology. Yellow latex (146)  was injected for contrast 
into the ascending aorta, major branches, and descending thoracic aorta in WT (100% elastin), Eln+/- (50-
60% elastin), and hBAC-mNull (30-40% elastin) mice. With decreasing elastin amounts, the aortic diameter 
decreases and the length increases. There are also changes in branching morphology with reduced elastin 
amounts. Scale bars = 1 mm. 
50 – 60% elastin 
Elastin heterozygous (Eln+/-) mice live a normal lifespan, but have hypertension, increased 
arterial structural stiffness (Figure 2.4), and an increased number of lamellar units in the arterial 
wall (Figure 2.5) (82, 134). Treatment with mTOR inhibitor rapamycin prevents the formation of 
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increased lamellar units in Eln+/- mice (144). Eln+/- arteries show reduced in vivo axial stretch, 
residual torsion (81), and increased length (Figure 2.6). Increased arterial structural stiffness 
precedes increases in blood pressure compared to WT mice during maturation, indicating that it 
may be a causative factor in the development of hypertension in Eln+/- mice (147). Eln+/- mice 
have indications of diastolic dysfunction, which may be linked to compromised arterial 
Windkessel function and decreased cardiac perfusion during diastole (148). Eln+/- mice have 
impaired glucose metabolism (149) and altered susceptibility to atherosclerotic plaque 
accumulation (150, 151).  Genetic modifiers of the Eln+/- cardiovascular phenotype have been 
identified by outcrossing Eln+/- mice. Several genes, including Ren1, Ncf1, and Nos1 were 
identified that may synergize with elastin insufficiency to predispose an individual to 
hypertension and increased arterial structural stiffness (152). Treatment of Eln+/- mice with anti-
hypertensive medications improves pulse pressure and subsequently physiologic structural 
stiffness due to the shift in operating pressures, but does not change material stiffness of the 
arteries (153). Treatment of Eln+/- mice with minoxidil, a KATP channel opener and vasodilator, 
also improves physiologic structural stiffness (154). Eln+/- mice have reduced susceptibility to 
vascular calcification (Figure 2.7) (155). Mice with reduced elastin due to a large genetic 
deletion that mimics the heterozygous deletion observed in WBS (135) have hypertension and 
increased arterial stiffness, but do not have the increased number of lamellar units observed in 
Eln+/- mice (136).  
 
30 - 40% elastin 
Eln-/- mice can be rescued by genetic insertion of a BAC expressing the human elastin gene 
(139). These hBAC-mNull mice have 35% of normal elastin amounts in the ascending aorta, 
have extreme hypertension, and increased arterial structural and material stiffness (Figure 2.4) 
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(139). Increased arterial structural stiffness has been confirmed in vivo using ultrasound imaging 
and may be caused by additional collagen amounts in the aortic media (Figure 2.5) and increased 
wall thickness (140). While lesion development in SVAS is attributed to VSMC 
overproliferation in the aortic media, Jiao et al. showed that deficient circumferential growth that 
limits outward expansion of the aorta, combined with normal VSMC proliferation is a 
mechanism for luminal narrowing in hBAC-mNull mice (140). Inhibiting mTOR with rapalogs 
does not prevent luminal narrowing in hBAC-mNull mice, but prevents the observed collagen 
fibrosis and arterial structural stiffening (156). hBAC-mNull mice have a longer aorta than WT 
(Figure 2.6) and the axial growth may be a compensation mechanism for the deficient 
circumferential growth (157). 
 
2.4.4 Acquired cardiovascular diseases 
Due to the limited time frame of elastin synthesis, elastic fibers that are damaged or degraded 
with aging or disease are generally not repaired. Elastic fibers are then replaced by collagens and 
proteoglycans that stiffen the arterial wall and lead to hypertension and damage to downstream 
organs. The ratio of elastin:collagen in the human aorta decreases 30 – 40% with age from the 
2nd to the 9th decade of life (158). In aging primates, it was recently observed that the 
elastin:collagen ratio changes with age, but disarray of the remaining elastic and collagen fibers 
may be an even more important contributor to increased arterial stiffness with aging (159). Many 
acquired diseases represent accelerated or exacerbated versions of the arterial remodeling 
observed with aging. The cardiovascular diseases discussed in this review, with a focus on elastic 
fibers and arterial mechanics, include hypertension and arterial stiffening, diabetes, obesity, 
atherosclerosis, calcification, and aneurysms and dissections. 
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Hypertension and arterial stiffening 
Hypertension is frequently observed in conjunction with diseases associated with defects in 
elastin or elastic fibers (160). While hypertension is typically associated with aging, the 
coincidental occurrence of hypertension in infants with SVAS indicates that age related factors 
are not required for SVAS associated hypertension (127, 128) and that elastin insufficiency 
likely plays a key role. Modulation of TGF-ß availability by Emilin-1, an elastic fiber associated 
protein, determines systolic blood pressure in mice, supporting a role for elastic fiber integrity 
and TGF-ß signaling in hypertension (161). TGF-ß is an important regulator of ECM remodeling 
in the arterial wall (162). Inflammatory signaling stimulated by EDPs from elastic fiber 
degradation may also play a role in hypertension. Reduced amounts of elastin or compromised 
elastic fiber integrity and the subsequent alterations in ECM composition and arterial geometry 
lead to increased material and/or structural arterial stiffness. While hypertension has long been 
associated with changes in resistance of the small, muscular arteries, it is now appreciated that 
increased stiffness of the large arteries can contribute to hypertension. The role of large artery 
stiffness in hypertension has been reviewed by Greenwald (70), Wagenseil and Mecham (85), 
and Mitchell (163), among others. Targeting ECM remodeling and the resulting changes in 
arterial stiffness represent a challenging, but potentially effective treatment for hypertension 
(164). 
 
Spontaneous hypertensive rats (SHR) are an animal model for essential hypertension developed 
through selective breeding (165). In young and adult SHR, systolic blood pressure is increased 
over Wistar-Kyoto rats (WKY), but material stiffness of the thoracic aorta is not different (166), 
indicating that increased stiffness of the large arteries does not precede hypertension in SHR. 
SHR have reduced elastin amounts, smaller arterial diameter, and increased structural stiffness of 
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the mesenteric resistance arteries compared to WKY, suggesting that increased resistance of the 
distal arteries contributes to hypertension development in SHR (167). With aging, aortic material 
stiffness dramatically increases in SHR compared to WKY (166). The increased stiffness has 
been attributed to endothelial dysfunction (168), increases in advanced glycation end products 
(169), and decreases in the elastin:collagen ratio (170) in aged SHR aorta compared to WKY. 
These results imply that SHR is not an appropriate model to investigate large artery stiffness in 
the development of hypertension, but is an appropriate model to investigate mechanisms of ECM 
remodeling and increased arterial stiffness in aging coupled with hypertension.  
 
Genetic factors associated with selective breeding of inbred rat strains are linked to changes in 
amount and organization of the aortic ECM. Behmoaras et al. found that aortic, blood pressure, 
elastin, collagen and cytokine amounts, and elastic laminae structure are different among seven 
inbred rat strains (171). Of the seven strains, the Brown-Norway rat (BNR) has the lowest aortic 
elastin amount and the lowest elastin:collagen ratio, leading to increased structural stiffness of 
the aorta compared to young LOU control rats (172). BNR are normotensive, suggesting that 
they are a good model for investigating interactions between elastin and arterial stiffness that are 
independent of changes in blood pressure. Treatment of cultured BNR VSMCs with potassium 
channel openers (minoxidil or diazoxide) increases tropoelastin transcription and mRNA 
stability. Treatment of BNR rats with minoxidil or diazoxide increases aortic elastic fiber content 
(173). In contrast, treatment of Eln+/- mice with minoxidil increases arterial size and stimulates 
differential expression of 127 matrix or matrix-associated genes, but does not show an elastin 
specific effect (154). Therapeutic options for increasing elastic fiber content may depend on the 
primary cause of the elastinopathy. 
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Diabetes 
In diabetes, the body does not produce or respond to insulin appropriately, leading to increased 
blood glucose levels. In vitro studies have examined the effects of increased glucose on VSMCs, 
isolated arterial elastin, and arterial mechanical behavior. High glucose media, with the addition 
of EDPs and TGF-ß1, increases expression of osteogenic genes in cultured VSMCs and may lead 
to arterial calcification associated with diabetes (174). Incubation of isolated arterial elastin in 
high glucose solution increases the storage and loss modulus, indicating an increase in material 
stiffness and viscous energy loss (175). After 48 hours of incubation in a high glucose solution, 
Zou and Zhang found an increase in the material stiffness of isolated arterial elastin in the 
longitudinal direction, but not in the circumferential direction (176). With incubation times up to 
28 days, Wang et al. found an increased material stiffness in both longitudinal and 
circumferential directions, as well as increased hysteresis (or energy loss) (177). The mechanical 
changes in isolated arterial elastin have been attributed to the dehydrating effects of glycation 
(175), but it is unclear how these results translate in vivo for an intact arterial wall with ECs 
acting as an impermeable barrier. Assuming that the glucose can reach the medial layers, 
increased glucose may lead to glycation of elastic fibers that alters stiffness and protease 
susceptibility. 
 
In a rat diabetic model, glycation increases over time in arterial samples as diabetes develops, but 
is unchanged in control rats (178). Diabetic rats also have reduced elastin protein levels in aortic 
extracts, as well as an increase in elastolytic activity (179). Decreased elastin:collagen mRNA 
ratio and increased structural stiffness of the aorta are observed in the leptin-receptor deficient 
mouse model for type 2 diabetes (db/db). Interestingly, the same study found opposite trends in 
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the elastin:collagen mRNA ratio and structural stiffness for the db/db coronary artery (180). 
Human diabetic patients similarly show a decrease in elastin:collagen protein ratios in aortic 
tissues (181) and an increase in circulating CatS levels (182). There are increased EDP levels in 
diabetic children (183), indicating that degradation of elastic fibers may occur in diabetes that 
contributes to arterial stiffening and inflammatory signaling. EDPs may also contribute to 
insulin-resistance and the onset of diabetes with aging (184). These results suggest that high 
glucose associated with diabetes may physically stiffen elastic fibers, as well as make them more 
susceptible to degradation, altering passive arterial mechanics and initiating a chemical signaling 
cascade through EDPs. 
 
Obesity 
Obesity is a risk factor for increased cardiovascular related mortality, but it is typically 
associated with additional cardiovascular risk factors including hypertension and diabetes. Rider 
et al. observed an increase in aortic PWV in obese patients absent other cardiovascular risk 
factors, providing evidence for a direct correlation between obesity and aortic structural stiffness 
(185). Elastin is decreased in adipose tissue of obese patients (186); however investigations on 
elastin and elastic fiber changes in large arteries from obese patients have yet to be performed. 
TGF-ß1 levels positively correlate with body mass index (BMI) in humans (187) and are 
upregulated in adipose tissue from obese humans (188) and mice (189). Cathepsin elastases, 
CatK, -L, and -S, have increased activity with increased BMI in humans and in the leptin-
deficient (ob/ob) mouse model of obesity (190). In ob/ob mice, aortic stiffening was observed by 
an increase in PWV, an increase in abdominal aorta structural stiffness in vitro, and an increase 
in thoracic aorta material stiffness as measured by AFM. Elastic fiber remodeling in the ob/ob 
aorta was evidenced by a decrease in LOX protein levels and activity, a decrease in desmosine 
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crosslinks, an increase in elastase activity, and higher degree of fragmentation in the elastic 
lamellae (191). The observed increase in aortic stiffness with obesity may arise from elastic fiber 
remodeling through LOX downregulation and an upregulation of elastolytic activity. 
 
Atherosclerosis 
Both the synthesis of tropoelastin and degradation of elastic fibers are increased in human 
atherosclerotic lesions (192). This may be due to the production of tropoelastin (193),  
metalloproteinases (194), and cathepsins (190) by macrophages  involved in atherosclerosis. 
Elastic fiber degradation allows infiltration of lipids and immune cells into the aortic wall for 
plaque formation and rupture in mice (195). EDPs resulting from elastic fiber fragmentation 
further enhance atherogenesis (100). TGF-ß1 activity, which may be modulated by elastic fiber 
degradation, has a wide range of effects in atherosclerosis (196). Elastin insufficiency and the 
associated increase in arterial structural stiffness do not increase atherosclerotic plaque 
deposition in mice (150, 151). Together, these results suggest that elastic fiber degradation and 
the resulting circulating peptides are key mechanisms linking elastin to atherosclerosis 
progression.   
 
Calcification 
Elastic fiber degradation has been linked to ectopic calcium phosphate mineral deposition 
(calcification) in the arterial walls, particularly in the medial layer. As demonstrated by Basalyga 
et al., periadventitial treatment of surgically exposed rat aortas with calcium chloride leads to 
ectopic mineral deposition along the elastic laminae (197). Calcified aortas of the treated rats 
show the presence of degraded ECM proteins, including elastin. Later, Khavandgar et al. showed 
that medial calcification in mice lacking matrix Gla protein (MGP), a potent inhibitor of soft 
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tissue calcification, is elastin-dependent (155). The amount of deposited minerals in Mgp-/- 
arteries scales with elastin amounts in the cardiovascular tree, with mineral deposition and elastin 
amounts decreasing from the thoracic to the abdominal aorta. Khavandgar et al. further showed 
that Mgp-/-Eln+/- mice have markedly reduced arterial mineral deposition compared to Mgp-/- 
mice (155) (Figure 2.7). This genetic experiment provides evidence that elastin content, and not 
just elastic fiber degradation, is a critical determinant of arterial medial calcification. 
 
Currently, the mechanism of mineral accumulation by elastin and how this process is inhibited 
by MGP is not well understood. Also, the role of elastin in intimal calcification associated with 
atherosclerotic plaques is still unknown. Future mechanistic work focusing on these aspects of 
elastin biology may lead to new therapeutic approaches to treat vascular calcification, for which 
no treatment is currently available 
 
Aneurysms and dissections 
Degraded and fragmented elastic fibers in the arterial wall are a common histopathology in 
thoracic and abdominal aortic aneurysms (198, 199). It appears that fragmented elastic fibers or 
improper elastic fiber deposition is critical to aneurysm formation, rather than reduced elastin 
amounts. ADCL1, characterized by improper elastic fiber deposition, is generally associated with 
aneurysms, while SVAS, characterized by elastin insufficiency, is generally not associated with 
Figure 2.7 - Effects of elastin amounts on 
medial calcification caused by MGP-
deficiency. Mgp-/- mouse arteries show 
extensive mineral deposition (black) along 
the elastic laminae (A), which is markedly 
reduced (arrows) in Mgp-/-Eln+/- mice (B). 
Thin plastic sections of the thoracic aortae 
from two week-old mice were stained with 
von Kossa and van Gieson (155). Scale bars 
= 20 μm. 
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aneurysms. Additionally, genetic mutations that affect proteins necessary for elastic fiber 
assembly, such as fibulin-4 (200) and lysyl oxidase (201), cause aneurysms. Loss of function 
mutations in genes that affect TGF-ß1 sequestration in the ECM, such as fibrillin-1, are 
associated with aberrant TGF- ß1 activity and aortic aneurysms (202). Fragmented, degraded, or 
improperly assembled elastic fibers may be more susceptible to protease digestion, allowing 
aneurysmal dilation over time and stimulating cytokine and inflammatory signaling. 
Homogenates of abdominal aortic aneurysms show high elastinolytic activity (198). Degraded or 
improperly assembled elastic fibers allow inflammatory cell infiltration, affect TGF-ß1 
sequestration, and the released EDPs can enhance macrophage activation (203) and TGF-ß1 
activity (104). 
 
Researchers have capitalized on the relationship between elastic fiber degradation, inflammatory 
cell activation, and chemokine signaling to generate a variety of chemically-stimulated models of 
abdominal aortic aneurysms and dissections in animals (204-206). The models include 
intraluminal or periadventitial application of elastase, periadventitial incubation with calcium 
chloride, and subcutaneous infusion of angiotensin II. Several of the models have been extended 
to create thoracic aortic aneurysms and dissections (207, 208). It is important to note that many 
of the chemically-induced animal models demonstrate aortic dilation and aneurysm formation, 
but do not progress to aortic rupture or dissection (209). Models that progress to rupture and 
dissection will be critical for translating the results of animal studies to treatment of human 
disease. 
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2.5 Tissue Engineering 
Increasing elastin amounts in genetic elastinopathies or repairing fragmented elastic fibers in 
acquired cardiovascular diseases are challenging problems. Tissue engineering, however, 
encounters the most challenging problem - recreating functional elastic fibers de novo. 
Elastogenesis has been called the “holy grail” of arterial tissue engineering, as the lack of mature 
elastic fibers in tissue-engineered constructs results in inferior mechanical properties compared 
to native arteries (210). Long and Tranquillo showed that the type of scaffold and cells chosen 
affects elastogenesis in tissue-engineered arteries, with increased elastin amounts secreted from 
neonatal compared to adult cells and on fibrin compared to collagen scaffolds (211). They also 
used chemokines known to increase steady state elastin mRNA expression, but the resulting 
elastic fiber structure in their constructs does not resemble arterial elastic laminae. Trying to 
replicate in vivo loading conditions, Kim et al. showed that long term application of 
circumferential cyclic strain increases tropoelastin mRNA and protein expression, along with 
increasing the material stiffness and ultimate tensile strength of tissue-engineered arteries, 
although the mechanical properties are still inferior to native aorta (212). Huang et al. recently 
showed that application of biaxial cyclic strain, more representative of the in vivo loading 
environment, produces tissue-engineered arteries with evidence of mature elastic fibers and 
improved mechanical properties compared to circumferentially strained constructs or constructs 
grown without cyclic strain (213). A tissue-engineered graft implanted as a pulmonary artery 
replacement in 8 week old lambs, exposed to cytokines and mechanical loading present in early 
maturation and growth, showed abundant elastic fiber deposition and about 50% of the insoluble 
elastin levels of the native pulmonary artery when evaluated 42 weeks after implantation (214). 
Overall, these results demonstrate the importance of reproducing the biochemical and 
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biomechanical environment of developing arteries to encourage elastogenesis in tissue 
engineering. 
 
2.6 Summary and Future Directions 
We have summarized genetic and acquired cardiovascular diseases linked to elastin and elastic 
fiber defects with a focus on large artery mechanics. Elastin and elastic fibers play a critical 
mechanical role at multiple length scales from pulse wave reflections in the cardiovascular 
system, to local material properties of the arterial wall, to interactions of tropoelastin with 
VSMCs. Elastin is a unique protein due to its limited time period of synthesis, long half-life, 
multi-step assembly process, and high degree of crosslinking that provides mechanical elasticity 
to the large arteries. Acquired damage to the elastic fibers is especially problematic due to the 
inability of the organism to generate de novo elastic fibers post-adolescence. Despite the 
increasing therapeutic options for controlling diseases such as hypertension, obesity, and 
diabetes, elastic fiber damage is currently irreparable meaning that the cardiovascular risks 
associated with arterial stiffness may persist even when other disease aspects are controlled. The 
process of elastic fiber assembly, especially inducing assembly in vitro or in vivo, is an active 
and important area of investigation for treating elastinopathies and the associated changes in 
cardiovascular mechanics, as well as advancing tissue engineering. 
 
We would like to highlight the differential effects of reduced elastin amounts compared to 
improper assembly or degradation of elastic fibers. Reduced elastin amounts lead to altered 
arterial wall structure, narrowed arterial lumen, increased arterial structural stiffness, and 
hypertension in humans and mice. In mice, the structural, mechanical, and functional phenotypes 
scale with elastin amounts. For the most part, mice appear to adapt reasonably well to 50-60% 
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elastin, with more severe phenotypes appearing when elastin amounts drop to 30-40% of normal. 
The mouse studies suggest that a threshold amount of elastin may provide near normal 
cardiovascular function in genetic diseases associated with elastin insufficiency. Hence, therapies 
that moderately increase elastin amounts, rather than completely restoring them to normal levels, 
may be sufficient for improved cardiovascular outcomes.  
 
Improperly assembled or degraded elastic fibers alter the passive mechanical properties of the 
arterial wall. The consequences extend far beyond physical changes to the elastic fibers to the 
initiation of several arterial remodeling events including VSMC phenotype modulation, ECM 
deposition, inflammatory cell infiltration, and the release of EDPs. EDPs stimulate cytokine 
signaling and activate inflammatory cells. The inflammatory cells secrete proteases that 
contribute to additional elastic fiber degradation in a positive feedback cycle. It is unclear 
whether the arterial remodeling signaling cascade is similar for genetic diseases with improperly 
assembled elastic fibers, such as ADCL1, and acquired diseases with elastic fiber degradation 
such as diabetes or abdominal aortic aneurysms. However, elastic fiber fragmentation, 
inflammatory signaling, and arterial stiffening are common factors in many of the cardiovascular 
diseases discussed in this review. Better understanding of the biochemical and biomechanical 
signaling associated with improperly assembled or degraded elastic fibers may allow therapeutic 
interventions that halt or slow down the arterial remodeling cascade and prevent disease 
progression. 
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Chapter 3
In vitro screening for Enhanced Elastic Fiber Crosslinking
by Drugs and Small Molecules
3.1 Introduction
Elastin has a myriad of physiological functions. As a major component of the arterial wall
extracellular matrix (ECM), elastic fibers influence the mechanical behavior of arteries.
Specifically, elastin provides elasticity to the large arteries, such that the wall can reversibly
deform in response to the pulsatile cardiac loading cycle. Mature elastin, soluble tropoelastin, as
well as elastin-derived peptide degeneration products have numerous signaling interactions that
affect biological development, vascular smooth muscle cell (VSMC) phenotype, and progression
of cardiovascular diseases including hypertension, atherosclerosis, and aneurysms. Loss of
elastin function in genetic or acquired elastinopathies is associated with an increased risk of
cardiac related death. For a more in-depth review on the role of elastin in physiology and disease,
refer to Chapter 2 of this dissertation.
Genetic or acquired elastinopathies are associated with structural damage and compromised
mechanical behavior in large arteries and small blood vessels. Tissue engineered blood vessels
(TEBVs) are being developed as suitable replacements. Unfortunately, many TEBVs lack burst
strength and elastic recoil that are essential to operate under the cyclic load of the cardiac cycle
(1-6). Nearly 50% of an artery’s dry weight is elastin, yet TEBVs have reduced elastic fiber
content and lack functional elastic lamellae (3, 5, 7). Despite the importance of elastic fibers to
50
the structural and mechanical integrity of the arterial wall, elastic fiber production in TEBVs has
been a challenge, severely restricting progress of the field (5). The ability to induce elastic fiber
assembly and develop functional elastic lamellae in vitro is considered a necessity for the
advancement of arterial tissue engineering.
The challenges associated with in vitro elastogenesis are likely a result of the complex temporal,
mechanical, and molecular interactions that regulate elastic fiber production and maturation
during in vivo development (8-10). Elastic fibers cannot be solubilized and then spontaneously
reassembled in vitro like many other ECM component fibers, such as type I collagen. Various
methods have been attempted in tissue engineering to induce elastic fiber assembly in vitro.
Berglund et al. generated TEBVs by seeding cells onto an elastic fiber scaffold isolated from
porcine carotids. While these TEBVs demonstrated improved mechanical properties over TEBVs
generated from a collagen scaffold, they were not comparable to native arteries. Additionally, the
matrix in the TEBVs did not demonstrate the capacity to restructure itself and, most importantly,
no de novo elastic fiber synthesis was observed (6). The addition of recombinant tropoelastin
(rTE) to non-elastin producing cells that maintain the expression of LOX results in the formation
of mature elastic fibers. However, adding rTE to elastin producing cells did not improve the
efficacy of elastic fiber synthesis (11). This result suggests that increasing the amount of
available tropoelastin is not sufficient to induce additional elastic fiber synthesis. Several studies
have demonstrated elastic fiber synthesis or elastin mRNA upregulation in response to
mechanical stimulation in vitro. However, this response appears to be dependent upon the
composition of the scaffold and the reported levels of mature elastic fibers are still low compared
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to native arteries (12-14). Also, at least one other study had conflicting results by demonstrating
attenuated elastic fiber production in response to mechanical stimulation (15).
Over 23 chemical and biological molecules have been shown to increase elastin expression,
however, the majority of these studies did not quantify mature elastic fibers (16). This is in large
part due to the lack of a ready method for quantifying mature elastic fibers, which is much more
challenging that quantifying soluble tropoelastin or expression of elastin mRNA (17).
Additionally, few studies have focused specifically on finding factors that induce mature elastic
fiber synthesis. Our study aims to develop a method for identifying factors that induce mature
elastic fiber synthesis through high-throughput screening of molecules.
There is an increasing interest in the discovery of small molecules that interact with proteins and
other biomolecules. Small molecule screening efforts have the potential to identify small
molecules with applications that extend beyond pharmacological use including the development
of investigative bioassays. Bioactive small molecules offer a complimentary strategy to genetic
modification strategies for discerning biological interactions, but offer advantages in that their
interactions with biomolecules are usually reversible and can modulate protein-protein
interactions that are difficult to investigate with genetic knockouts (18). A small molecule
screening platform could identify molecules with pharmaceutical potential in the treatment of
elastin deficient diseases. A small molecule inducer of elastic fiber synthesis could be used in
arterial tissue engineering efforts to develop TEBVs that better mimic the structure, strength, and
elasticity of native arteries. A screening technique will also be useful as an investigative tool for
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identifying factors that interact with elastic fiber synthesis to improve our understanding of the
elastic fiber synthesis pathway.
Generally, a high-throughput screening process occurs in three major steps; development of an
assay for a targeted biological activity, a primary screen of a high number of molecules, and a
secondary screen of positive hits from the primary screen to demonstrate a reproducible effect of
the molecule on the targeted activity. Initially, a target biological response must be identified,
and an assay must be designed to quantify the target activity in a manner that is specific and
robust. In the case of our screening efforts, the target biological activity is the formation of
mature elastic fibers in cell culture. The assay used to quantify elastic fiber maturation is a
competitive ELISA for desmosine, an amino acid that is unique to mature, crosslinked elastic
fibers, developed in Dr. Mecham’s lab. We performed several validation experiments to
demonstrate the ability of the desmosine ELISA to measure varying amounts of mature elastic
fibers. This included measuring temporal elastic fiber production in culture across a span of 2-14
days in culture and measuring a lack of elastic fibers in cultures treated with beta-
aminopropionitrile (ßAPN), an inhibitor of LOX which is the primary crosslinker of elastin (17).
Following target and assay selection, a primary screen is performed. Typical primary screens
may involve compound libraries containing over 100,000 molecules. The size of the library is
resource limited by factors including the per sample cost of the assay, the amount of time it takes
to perform the screen, and the degree to which automation can be incorporated. The screen we
performed may be more aptly described as a semi high-throughput screen because the compound
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library contains around 1600 molecules and the complexity of the cell culture conditions and the
desmosine ELISA are not readily adaptable to automation.
Primary screens prioritize high volume output and often the molecules are tested without
replication. It is necessary to check assay quality in high-throughput screens since generally
more robust and accurate assays have reduced risk of calling false-positives or false-negatives. A
parameter called the z-factor is a specialized statistical method to score the suitability of an assay
for high-throughput screening and is calculated by the following formula (19),
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where σ and μ are the standard deviation and mean, respectively, of the biological activity
measured for the samples (s) and positive controls (c+). The z-factor can be calculated to score
either the results of the entire screen, or the results from a single plate in the screen since plate-
to-plate variability can be large in many assays. An assay scoring a z-factor above zero is
suitable for high-throughput screening and assays approaching a z-factor of one have a greater
dynamic range for detection and/or decreased variability. If more than one assay for the target
biological activity is available, the z-factor can be used to determine which is better suited for
high-throughput screening.
The z-factor is a useful parameter; however it requires a positive control, which may not be
available. As part of this study, it was necessary to identify a positive control that could be used
in the screen. Several studies have reported increased elastic fiber maturation in vitro when
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certain growth factors were added to the culture media. Insulin promoted elastic fiber synthesis
in a concentration dependent manner in primary human aortic smooth muscle cells (20),
increased elastic fiber deposition was observed in human skin fibroblasts with the addition of
TGF-ß1 (21), and the combination of insulin and TGF-ß1 resulted in increased elastic fibers in
cardiovascular tissue-equivalents developed from primary neonatal rat smooth muscle cells (22).
As part of this investigation, we tested the effect of insulin and TGF-ß1 on elastic fiber
production on a rat lung fibroblast cell line, RFL6, to determine whether these growth factors
would be suitable positive controls in our screening platform.
Other potential positive controls may include pharmaceuticals that have demonstrated activity
towards increasing elastin expression and elastic fiber production in animal studies. Slove et al.
reported increased expression of the elastin gene and other genes associated with elastic fiber
synthesis in primary culture of VSMCs from Brown Norway (BN) rats treated with the
antihypertensive drugs diazoxide and minoxidil. The same study also reported increased elastic
fiber deposition in BN rats treated with either drug; however their method of quantifying elastin
content was not reported. (23) More recently, Knutsen et al. reported increased elastic fiber
deposition in elastin haploinsufficient mice treated with minoxidil, but they did not investigate
the effect of minoxodil on elastic fiber production in wild-type animals (24). To our knowledge,
none of these drugs have been specifically investigated for in vitro elastic fiber maturation prior
to our study. We performed our assay on RFL6 cells treated with one of each of three
antihypertensive drugs; diazoxide, captopril, and minoxidil.
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After completing the primary screen assay, hit-selection is performed on the results to identify
‘hits’, or agonists to the targeted biological activity. Several statistical methodologies have been
developed for hit-selection from a primary screen (25), and the appropriate method is dependent
on the design of the primary screen; number of replicates, availability of positive and negative
controls, and whether the results are normally distributed. For our primary screen, a single
measurement was collected for each molecule tested and a positive control was unavailable so
the appropriate method for hit-selection was to calculate the robust strictly standardized mean
difference (SSMD*) (25).
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In equations (3.2), (3.3), and (3.4), Y is the measured activity of the ith compound or negative
control (n). An assumption in the SSMD* is that the majority of the compounds tested will not
demonstrate agonistic activity and are treated as negative controls in the calculation such that Nn
is the total number of negative controls. Compounds with a SSMD* higher than 2.12 (SSMD*
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equivalent of three standard deviations above the plate mean) are positive hits in the primary
screen.
A secondary screen is performed following hit selection since the primary screen is susceptible
to variance and error. The secondary screen is a replication of the primary screen on only the
discovered hits and with increased experimental and technical replicates. Standard t statistics are
used to validate the activity of the hits from the primary screen. Any compounds which still
demonstrate agonistic activity are potential candidates for hit-to-lead development.
We describe the ELISA assay methods, investigation of positive and negative controls, and
screening process in the search for a compound that upregulates crosslinked elastic fiber
production in cell culture for future application in tissue engineering and treatment of
elastinopathies.
3.2 Methods
3.2.1 Cell culture
RFL6 cells retain the capacity to produce mature elastic fibers in the ECM in vitro (26) and were
used in this study as a platform for elastic fiber crosslinking. Immortalized RFL6 cells (ATCC,
CCL-192) were grown in T75 flasks in DMEM/F-12 culture media (MilliporeSigma, D8900)
supplemented with 10% fetal bovine serum (FBS) (Biowest, S1620, Lot# 316C13) until 80%
confluency. The cells were then detached with a brief trypsin treatment, cell density was
counted, and then 6- or 48-well culture treated plates were uniformly seeded at a cell density of
1.3∙104 cells/mL. At confluency (~3 days after plating) the FBS concentration in the culture
media was reduced to 5%, as FBS inhibits elastic fiber synthesis at higher concentrations (17).
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Additionally, at this point the cells were treated with the molecule or protein of interest. The
media and molecule/protein were replaced every two days and the cell culture was maintained
this way for two weeks post confluency.
Along with the molecule/protein treatments, two additional treatments were used as controls for
all screening studies. Beta-aminopropionitrile (ßAPN) is a known inhibitor of LOX activity and
is effective at preventing elastic fiber crosslinking (17). 100μg/mL ßAPN (MilliporeSigma,
A3134) was used in this study as an antagonistic control. The majority of molecules used to treat
the cells in this study were dissolved in (DMSO). DMSO is cytotoxic, and it was necessary to
perform a DMSO concentration dependence experiment to establish a DMSO concentration that
can be used without adversely effecting cell activity as measured from total protein content.
From the results, 0.1v/v% DMSO was chosen as the maximum allowed volume of DMSO for the
molecule library screening study and a vehicle control of DMSO was always included in the
screening studies, where appropriate. In the growth factor screen, recombinant human TGF-ß1
(rhTGF-ß1, R&D Systems, 240-B) and human insulin (MilliporeSigma, I0908) were dissolved in
4 and 10mM HCl, respectively, and the appropriate vehicle control was used. The final
concentration of TGF-ß1 and insulin in the culture media was 2.00∙10-3 and 2.00 ug/mL,
respectively, to replicate the experiments performed by Long and Tranquillo, 2003 (22). In the
antihypertensive study, the final concentration of diazoxide (MilliporeSigma, D9035), minoxidil
(MilliporeSigma, M4145), and captopril (MilliporeSigma, C4042) were 10, 6.5, and 30 μg/mL,
respectively, as determined by each molecule’s maximum solubility in DMSO and a final DMSO
concentration in the culture media of 0.1v/v%.
58
At the end of the treatment schedule for each experiment, the cells were rinsed two times with
PBS buffer. The cells were scraped from the culture plates and collected in vials. The cells were
immediately pelleted and dried using a SpeedVac concentrator (Savant, SPD131DDA) in
preparation for hydrolysis.
3.2.2 Cell pellet hydrolysis
The vials containing the cell pellets were enclosed in a hydrolysis chamber containing 100 uL of
sequencing-grade, 6 N HCl (Thermo Fisher Scientific, 24308) and an additional 10 uL HCl in
each sample vial. The hydrolysis chambers were then placed in an oven at 100°C for 48 hours,
completely reducing the cellular debris to amino acids. After hydrolysis the samples were dried
using a SpeedVac concentrator and then reconstituted in 100 μL of ultrapure water. From this
hydrolysate, elastin content is quantified using a competitive ELISA for desmosine and total
protein amount is quantified with a ninhydrin-based assay for amino acid content.
3.2.3 Competitive ELISA for desmosine quantitation
Mature elastic fiber content was quantified from the cell-pellet hydrolysates using a competitive
ELISA for desmosine that was originally developed in Dr. Robert Mecham’s lab (Washington
University School of Medicine in St. Louis) (27). All steps of the ELISA were performed at
room temperature. High binding 96-well plates (Corning, 9018) were coated with 50 μL coating
buffer (50mM carbonate/bicarbonate buffer, 9.6 pH) containing desmosine-ovalbumin protein
conjugate (Elastin Products Company, DOC375) for a 30-minute incubation. The coated plates
were then blocked with 100 μL of blocking buffer (KPL, 50-61-01) for 15 minutes before being
washed thrice with washing buffer (KPL, 50-63-01). A volume of 20 μL or 10 μL of the 100 μL
hydrolysate from cells grown on 48- or 6-well plates, respectively, was added to the plate in
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triplicate along with enough 0.5 M sodium phosphate buffer (7.8 pH) to bring the final volume to
50 μL. An elastin standard curve was made from either a serial dilution of hydrolyzed, purified
bovine ligament elastin (Elastin Products Company, E60) or a serial dilution of desmosine
(Elastin Products Company, D866). Primary antibody binding was initiated by adding 100 μL of
1:2000 diluted anti-serum raised in rabbits against bovine desmosine (provided by Dr. Barry
Starcher’s lab, University of Texas Health Science Center). This step introduces competitive
binding between the desmosine that is conjugated to the ovalbumin bound to the plate and the
desmosine from the sample or standard freely suspended in the well. After a 60-minute
incubation period, the plate was washed again and 100 μL of 1:2000 goat anti-rabbit IgG
conjugated horseradish peroxidase (Gar-HRP) (KPL, 074-1506) was added to each well to
initiate secondary antibody binding. After another 60-minute incubation period, a final wash was
performed and 100 μL of TMB substrate (KPL, 52-00-00) was promptly added to each well.
TMB oxidizes HRP yielding a water-soluble reaction product that is blue in color. Color
intensity of each well was measured spectrophotometrically at 650 nm detection with a plate
reader (Molecular Devices, SpectraMax M2e) at 5-minute intervals for 20 minutes. A standard
curve was generated by performing a four parameter logistic regression on the absorbance values
measured for the standards. An example of the desmosine ELISA standard curve a regression fit
is included in Figure 3.1. Raw absorbance of each sample was converted to either elastin or
desmosine concentration by comparing against the standard curve and using the 10-minute
reading which was consistently below the signal saturation limit.
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3.2.4 Ninhydrin assay for total protein quantitation
Total protein content was used to normalize elastin content for the cell-pellets and was measured
using a ninhydrin-based assay for amino acid content (28). Briefly, 2 μL or 1 μL of the 100 μL
hydrolysate from cells grown on 48- or 6-well plates, respectively, was added to a standard 96-
well plate (Thermo Fisher Scientific, 12-565-501) in triplicate. A standard curve was prepared by
adding regular increments of amino acid collagen hydrolysate calibrator (Pickering Laboratories,
012506C) from 12 μL down to 0 μL in duplicate to the plate. The ninhydrin working reagent was
prepared fresh and 100 μL of the reagent was added to each well of the plate. The plate was
covered and placed on an enclosed hotplate for a 10-minute incubation period at 85°C.
Absorbance at 575 nm was measured with a plate reader (Molecular Devices, SpectraMax M2e)
and a standard curve was generated by linear regression of the standards. Total protein content of
the samples was determined by comparing the raw absorbance of the samples against the
standard curve.
3.2.5 Small molecule library NCI Diversity Set V
The Diversity Set V small molecule library was obtained from the Developmental Therapeutics
Program (DTP) of the National Cancer Institute (NCI). This library of 1593 compounds was
a
d
c
b
Figure 3.1 – Example of non-linear regression
with the four-parameter logistics model of the
elastin standard curve used in the desmosine
ELISA.
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derived by DTP from their molecule repository of over 140,000 compounds based on
pharmacophoric diversity; each compound having at least five unique pharmacophores from the
other compounds in the library. All compounds were dissolved in DMSO at 10 mM
concentration.
3.2.6 Small molecule library primary screening
A total of 50, 48-well culture treated plates seeded with RFL6 cells were prepared and processed
as described in section 3.3.1. Each plate was treated with 100 μg/mL ßAPN in three wells, 0.1
v/v% DMSO in three wells, and two wells were untreated. The remaining wells were each
treated with one of the compounds from the NCI Diversity Set V library such that 40 different
compounds were screened on every culture plate. Each compound was dissolved in DMSO and
was administered to the cell culture at 0.1 v/v% such that the final molarity was 0.01 mM. As
common practice with primary screening of high volume libraries, each compound was tested
without replicates to reduce the time and resources necessary to screen the complete library.
After the 14-day treatment schedule the cells were collected, hydrolyzed, and the biochemical
assays were performed as described in previous sections.
3.2.7 Small molecule library hit selection and primary screen verification
Hit selection from the results of the primary screen was performed by calculating the SSMD*
(equations (3.2), (3.3) and (3.4)) of each tested molecule on a per plate basis, assuming all other
molecules on the plate were negative controls. Molecules scoring an SSMD* greater than 2.12,
which is equivalent to three standard deviations above the plate mean, were denoted as positive
hits. To account for variance in the biochemical assays, the remaining sample from the positive
hits was used to quantify elastin and total protein again, this time using three technical replicates.
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Only samples that held an elastin-to-total protein ratio three standard deviations above their
respective DMSO controls were maintained as positive hits.
3.2.8 Small molecule library secondary screening and replication
A secondary screen of the positive hits identified in the primary screen was performed. The
remaining molecule solutions were used to repeat the treatment of RFL6 cells as described
previously. This time, experimental replicates were used (n = 4 for each molecule) and the
desmosine ELISA and ninhydrin total protein assay were performed in triplicate for each sample.
A student’s t-test was performed to determine significant increases in elastin-to-total protein
ratios of each treatment compared to a DMSO control group. Additional aliquots of each
molecule that maintained an increase in mature elastic fiber production was kindly provide by
DTP so that additional studies could be performed. Verification experiments of the newly
acquired aliquots were performed by repeating the secondary screen but with an increased
number of experimental groups (n = 6).
3.3 Results
3.3.1 Time course in vitro elastic fiber synthesis
Elastic fiber production in vitro tends to occur at a slower rate than other ECM proteins, and the
rate of production may be cell-type specific (17). To establish a length of time for culture
incubation to maximum detection with the desmosine ELISA we performed a time course
experiment (Figure 3.2A). We detected a strong linear correlation (R2 = 0.85) of desmosine
content with length of post-confluent culture time, and the elastic fiber content increased 3.71-
fold from day 2 to day 14. From these results, we decided to use a post-confluent culture time of
14 days. Although longer time periods were not tested, 14 days generated sufficient elastic fibers
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to quantify and increasing the culture time period would expend additional resources
unnecessarily and would increase the risk of culture contamination.
3.3.2 ßAPN as an inhibition control
A ßAPN concentration of 100 μg/mL is sufficient for severe inhibition of LOX activity to
crosslink tropoelastin into mature elastic fibers (17). We compared desmosine content of ßAPN
treated RFL6 cells grown on 6-well culture plates to untreated cells. Using t-test statistics, we
identified a significant (p = 0.0003) 92.4% reduction in desmosine content from ßAPN treated
cells (Figure 3.2B) with a corresponding 91.2% reduction (p = 0.0011) in desmosine-to-total
protein ratio, while total protein content remained unchanged (p = 0.424). Our results provide
verification of the inhibitory activity of ßAPN within our RFL6 cell culture and demonstrate the
capability of the desmosine ELISA to detect the presence and absence of mature elastic fibers
produced in vitro.
3.3.3 DMSO cytotoxicity
At high enough concentrations, DMSO is toxic to cells and we performed a concentration profile
experiment to determine what amount of DMSO can be added to RFL6 cells in culture before
adverse effects are observed. The ninhydrin total protein assay was used as a proxy to
quantifying cellular activity since changes in cellular processes and cell viability would be
reflected in the overall protein content of the cell pellet. The results of this toxicity study are
presented in Figure 3.2C. A one-way ANOVA was performed, and demonstrated a significant
relationship between DMSO concentration and total protein content (p < 0.0001, R2 = 0.903). A
Bonferroni’s multiple comparisons test was performed to determine p-value significance
between each DMSO treated group and the untreated control group. The groups exposed to 1.0
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and 0.5 v/v% DMSO had a significant 49.5% (p < 0.0001) and 18.6% (p = 0.0094) reduction,
respectively, in total protein content. The group exposed to 0.1 v/v% DMSO was not
significantly changed (p > 0.9999) from the control group. All proceeding experiments were
performed using 0.1 v/v% DMSO.
Figure 3.2 - Results from the elastic fiber screening platform development in cultured RFL6 cells. A)
Temporal study demonstrating increased elastic fiber assembly over time through the measure of desmosine
content. # indicates one-way ANOVA significance (p < 0.0001) and * indicates significance from a
Bonferonni’s multiple comparisons test for the 12 and 14 day samples (p = 0.0186 and p < 0.0001,
respectively) in comparison to 2 days. B) Demonstrated elastic fiber assembly knockdown through the
inhibition of LOX crosslinking by ßAPN. * indicates significance (p = 0.0003) by student’s t-test between
groups. C) Cytotoxicity of DMSO on cultured cells. # indicates significance in total protein content with
DMSO volume concentration percentage by one-way ANOVA (p < 0.0001). * Higher DMSO concentrations
had significantly reduced total protein compared to untreated cells by Bonferroni’s multiple comparisons test
(p < 0.01) whereas the cells treated with 0.1 v/v% DMSO has no significant difference in total protein.
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3.3.4 Suitability of insulin and TGF-ß1 as positive controls
Ideally, a positive control for mature elastic fiber production would be used in the small
molecule library screen in order to perform a z-factor analysis to gauge the suitability of the
desmosine ELISA for high-throughput screening. However, there is a lack of known factors
capable of upregulating elastic fiber synthesis in vitro. A combination of insulin and TGF-ß1
demonstrated elastic fiber production in cardiovascular equivalents by Long and Tranquillo,
2003 (22). We performed our screening method to determine whether these growth factors could
induce elastic fiber formation in our RFL6 cells and be used as a positive control for the small
molecule library screen. The resulting desmosine-to-total protein ratio is presented in Figure 3.3.
All treatment groups used HCl as a solvent for the growth factors and so an HCl vehicle control
matching the highest HCl concentration of the treatment groups was used in addition to an
untreated group. A one-way ANOVA was performed on the results, and a Bonferroni multiple
comparisons test was used to compare individual experiment groups. All groups containing HCl
resulted in a significant (p < 0.0001) reduction in elastic fiber production compared to the
untreated group. In comparison to the HCl vehicle control, the insulin and TGF-ß1 groups were
unchanged but the group treated with both growth factors resulted in a 1.75-fold increase (p =
0.0049) in elastin-to-total protein ratio. There were no significant changes in the total protein
Figure 3.3 - Measured desmosine-to-total
protein ratio using our elastic fiber assembly
screening platform and a treatment with
growth factors insulin and TGF-β1. Growth
factors were solubilized in HCl and an HCl
vehicle control was included. # indicates
significant (p < 0.0001) reduction in the ratio in
groups containing HCl compared to the
untreated group through Bonferroni’s multiple
comparisons test. * represents significant
increases (p = 0.0049) in treatment groups
compared to the HCl vehicle control.
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levels acquired from the ninhydrin assay, indicating the changes observed in the ratio are
attributable to changes in elastic fiber production.
The z-factor parameter (equation (3.1)), using the combined insulin and TGF-ß1 treatment as the
positive control and the HCl vehicle as the sample, was determined to be -1.18. This z-factor
would indicate that our assay is too unreliable to be used in a high-throughput screen, however
the result is complicated by the observed reduction in elastic fiber production by the HCl control.
This z-factor is not indicative of how the screen would perform because the molecules from the
library are dissolved in DMSO rather than HCl. Hence, we decided not to use insulin and TGF-
ß1 as a positive control.
3.3.5 Suitability of antihypertensive drugs as positive controls
The result of the antihypertensive drug screen on mature elastic fiber production is presented in
Figure 3.4. A one-way ANOVA and Bonferroni’s multiple comparisons test was performed on
the results. Only the ßAPN inhibition control demonstrated a significant change compared to
either the DMSO (p = 0.004) control. None of the antihypertensive drugs tested demonstrated
increased elastic fiber production. Hence, the antihypertensive drugs were also not a suitable
positive control for the small molecule library screen.
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3.3.6 Primary screening
We proceeded with the small molecule screen with a negative control (ßAPN), but no positive
control. The results of the primary screen of the nearly 1600 molecules from the NCI Diversity
Set V small molecule library are presented in Figure 3.5 as a scatterplot of the total protein
content on the x-axis and elastin content on the y-axis. Control groups treated with either ßAPN,
0.1v/v% DMSO, or untreated are also presented on the plot. Without a control for positive
upregulation of elastic fiber product a z-factor cannot be determined, however the relative
clustering of the control groups on the scatter plot can provide some indication of the
reproducibility of the screening process.
The ßAPN controls from all 25 assay plates appear to cluster low on the elastin content-axis, as
expected, but there is a large spread on the total protein content-axis. The ninhydrin total protein
assay is very robust, so this spread is likely an indication of variability in the cell culture
conditions.  The DMSO and untreated controls cluster together on both axes, indicating that
DMSO is not having an effect on either the elastin or total protein content. The samples that are
treated with one of the molecules from the library have a wide range on both axes. Any sample
deviating outside of the range of either the DMSO or untreated control may be an indication that
Figure 3.4 - Measured desmosine-to-total
protein ratio using our elastic fiber assembly
screening platform and treatment of the
RFL6 cells with antihypertensive drugs
diazoxide, captopril, and minoxidil. Only the
βAPN negative control demonstrated a
significant change from either DMSO vehicle
control (*, p = 0.0040) or untreated control
(#, p = 0.0023) by Bonferroni’s multiple
comparisons test.
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the molecule has some bioactivity within our cell culture. In the case of total protein content,
samples that are lower than any of the control groups could be an indication that the molecule
has some level of cytotoxicity. Samples that are below zero on the total protein-axis did not have
a cell pellet at the end of the two-week culture. These samples still have a minimal level on the
elastin content-axis indicating that this is likely the level of background noise for the desmosine
ELISA. This observation is corroborated by the results of the ßAPN controls which have a
similar range on the elastin content-axis.
Figure 3.5 - Scatterplot presenting the results of the primary screen of the NCI Diversity Set V small
molecule library from DTP. Total protein content is shown on the x-axis and elastin content on the y-axis.
The entirety of the screen occurred over 50 48-well plates of cultured RFL6 cells and 25 96-well plates for
each of the biochemical assays. βAPN inhibitory control, DMSO vehicle control and untreated controls
from each culture plate are included on the scatterplot. Each small molecule treatment was performed
without experimental or technical replicates. Controls had multiple experimental replicates but no
technical replicates.
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The SSMD* parameter, calculated using equations (3.2), (3.3), and (3.4), for every molecule in
the library is present in a histogram in Figure 3.6A. Any sample having an SSMD* greater than
2.12 is scored as a positive hit, of which there were 21 in total. Samples having an SSMD* less
than -2.12 may potentially be a negative hit, however all of those samples also lacked a cell
pellet or had very low total protein content. Rather than negative hits, these samples either
resulted from a cytotoxic effect of the molecule or the cell culture was inviable for other reasons.
Without a z-factor calculation and because of the apparent variability of the desmosine ELISA,
the biochemical assays were repeated on the remaining sample for each of the positive hits and
Figure 3.6 - Hit selection of the primary screen
and verification of the primary screen positive hits
by increased biochemical assay technical
replicates of the remaining sample collected in the
primary screen. A) Histogram of the SSMD*
parameter calculated for each small molecule
tested in the screen. Treatments scoring an
SSMD* greater than 2.12 are positive hits, of
which 21 were tabulated and were used in
subsequent screening. B) Elastic fiber content and
total protein content measures were repeated
witch three additional technical replicates along
with their respective DMSO controls. * indicates
the treatments that maintained an elastin-to-total
protein ratio greater than three standard
deviations above DMSO control. In total, 7
molecules were maintained as positive hits and we
used in the subsequent secondary screen.
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their respective DMSO control, this time in triplicate. The results of this primary screen
validation experiment are presented in Figure 3.6B. Of the 21 molecules scored as positive hits
in the primary screen, only seven molecules maintained an elastin-to-total protein ratio that was
three standard deviations above their respective DMSO control. These seven molecules were
used in the secondary screen of this study.
3.3.7 Secondary screening
The results from the secondary screen are
presented in Figure 3.7A as the elastin-to-
total protein ratio of each of the seven
positive hits and respective DMSO
controls from the same cell culture plate.
A student’s t-test was performed to
compare the result of each treatment to
the DMSO control. Molecules 3B6 (p =
0.0303) and 18B5 (p = 0.0154) were
significantly increased while these rest of
the molecules were statistically
unchanged. Additional stock of molecules
3B6 and 18B5 were requested from, and
kindly provided by, DTP for additional
experimentation. A secondary screen
validation experiment was performed with
Figure 3.7 - Elastin-to-total protein ratios of the 7
primary screen positive hits in a secondary screen (A)
and secondary screen validation (B). A) Treatments in
the secondary screen were performed with four
experimental replicates and three technical replicates. *
indicates significance by student’s t-test molecules 3B6 (p
= 0.0303) and 18B5 (p = 0.0154) compared to their
respective DMSO controls. B) Additional stock of
molecules 3B6 and 18B5 was received from DTP and a
validation screen was performed with six experimental
replicates and three technical replicates. There was no
statistical difference between treated and untreated
groups.
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these two molecules (Figure 3.7B), however neither of them demonstrated significantly
increased elastic fiber production.
3.4 Discussion
High-throughput screening is a high-risk method for identifying bioactive molecules, but the
discovery of such molecules could have tremendous positive impact on the area of interest. In
our study, the identification of a molecule with elastic fiber synthesis inducing activity could
have positive impact on the development of pharmaceutical therapies for diseases related to
genetic or acquired elastic fiber deficiency. Additionally, this molecule could move the tissue
engineering field forward in the development of TEBVs that better mimic the structural,
mechanical, and biochemical properties of native arterials and blood vessels. While an inducer
was not uncovered from our screening efforts, we have demonstrated that our platform has the
capacity for semi high-throughput screening and serves as a proof of concept. With further
improvements on the reliability of the platform it could be used for future screens.
Our platform could also be used to screen factors that have been identified as upregulators of
tropoelastin expression for the presence of increased mature elastic fiber production.
Approximately 19 molecular factors have been shown to upregulate elastin gene expression,
however it has been shown that increased levels of tropoelastin (elastic fiber precursor) is not
sufficient for de novo elastic fiber synthesis (11, 16). The majority of these factors are untested
for their effect on elastic fiber synthesis.
One improvement needed for our platform is the identification of suitable positive control, but
the lack of rigorously tested factors that induce elastic fiber formation is a limitation. While the
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combination treatment of insulin and TGF-ß1 did increase elastic fiber production compared to
the HCl control, the overall effect of HCl on reducing elastic fiber production was unexpected.
The final HCl concentration experienced by the cells was 52 μM. This low concentration is not
expected to drastically change the pH of the culture media and no change to the color of the
phenol red in the media was observed. Within a limited context, our results of the growth factor
study confirmed the results observed in Long and Tranquillo, 2003. This demonstrated the utility
of our platform outside of high-throughput screening.
We also evaluated three antihypertensive drugs; diazoxide, captopril, and minoxidil to
potentially serve as positive controls. Diazoxide and minoxidil have been shown to upregulate
tropoelastin expression in vitro, (23) however our results indicate that none of these drugs have
an effect on crosslinked elastin amounts in our RFL6 cell culture. Recently, minoxidil treatment
in Eln+/- mice demonstrated increased elastic fiber deposition compared to untreated Eln+/- mice,
however this study did not report any results on minoxodil treated Eln+/+ mice (24) The result in
our study with minoxidil further establishes that upregulation of tropoelastin expression is not
sufficient for increased elastic fiber crosslinking and any elastic fiber maturation inductive
activity may be dependent on factors including cell type, in vitro/in vivo experimentation, or the
genetic predisposition of the organism.
Another potential improvement that could be developed for our screening platform is to limit the
scope of the bioactivity that we are interested in from a potential molecule enhancer. Elastic fiber
assembly is a complex process that may involve as many as 30 proteins, many of which have an
undiscovered role in the process (29). Elastic fiber assembly is also a multi-step process and it is
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unclear which steps may be rate-limiting in vitro. The desmosine ELISA we used in our
screening platform specifically targets elastic fiber crosslinking, thereby quantifying the final
product of the elastic fiber synthesis pathway. While an increase in mature elastic fibers is the
desired effect, there may not be any one single molecule with the bioactivity to accomplish this.
It is possible that multiple components of the elastic fiber synthesis pathway are required to be
independently influenced to induce mature elastic fiber production. The requirement of both
insulin and TGF-ß1 to produce higher levels of elastic fibers than the HCl control is an example
of the requirement of multiple factors. TGF-ß1 is believed to promote elastic fiber synthesis by
through the stabilization and subsequent accumulation of elastin mRNA (30-32). Insulin may
have a role in triggering transcription of the elastin gene and insulin signaling may promote the
transport of tropoelastin to the cell membrane (20). It is possible that the cells need to be made
more amendable towards elastic fiber synthesis by the inclusion of these growth factors in order
to be able to screen a molecule library for agonistic activity.
3.5 Summary
We developed a platform for screening mature elastic fiber production and used this platform to
screen the NCI Diversity Set V library of 1593 small molecules provided from DTP. A
competitive ELISA for desmosine was used to determine mature, crosslinked elastic fiber
content produced by RFL6 cells in culture. To account for plate-to-plate variance in the cell
culture conditions, total protein content determined by a ninhydrin assay was used normalize the
results of the desmosine ELISA. Using ßAPN, an inhibitor of elastin crosslinking, we
demonstrated that the ELISA can detect the presence and absence of elastic fibers in our
platform (Figure 3.2B). We performed a time course study to determine that 14-days in culture
was sufficient for RFL6 cells to produce high levels of elastic fibers (Figure 3.2A). We
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determined that 48-well plates are the smallest surface area from which the ELISA can detect
desmosine, but when possible, 6-well plates were used to more reliably generate desmosine
amounts within range of the ELISA.
The molecules from the Diversity Set V library were dissolved in DMSO, which is cytotoxic at
higher concentrations. We performed a concentration profile experiment to identify the highest
liquid volume percentage of DMSO could be exposed to cells without significantly inhibiting
cellular activity, as measured by total protein amounts (Figure 3.2C). We decided a maximum of
0.1 v/v% would be used in our studies.
With our platform we performed a primary screen on nearly 1600 small molecules from a library
donated by the Developmental Therapeutics Program (DTP) of the National Cancer Institute
(NCI). From the primary screen, 21 potential hits were identified and 7 of them were maintained
as positive hits after a validation study of the primary screen results. The reduction of positive
hits on increasing the technical replicates performed on the same samples from the primary
screen indicate that the biochemical assays used in our platform, in particular the desmosine
ELISA, may be too variable and have too much background noise to reliable select positive hits
from a high-throughput screen.
A secondary screen was performed on the 7 positive hits, this time with increased experimental
and technical replicates. As a result, two of these molecules demonstrated potential elastic fiber
synthesis enhancement. Additional validation experiments were performed on these two
molecules, however the enhanced elastic fiber production activity was not reproducible.
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Despite our efforts, a novel elastic fiber promoting molecule was not discovered in our screen.
Regardless, the adaptation of the desmosine ELISA from Dr. Mecham’s lab has enabled our lab
to investigate elastic fiber content in several tissues. I have contributed my acquired biochemical
assay expertise to numerous investigations including results presented in two publications and
ongoing research in our lab.(33, 34)
3.6 Limitations
SSMD* hit selection is only capable of detecting strong effectors from a primary screen.
Molecules from the library that have a subtle influence on the target process, in this case elastic
fiber synthesis, would be hidden as false-negatives. This is a weakness of the statistical method
because, although strong effectors are most desired, weaker effectors could theoretically contain
a useful pharmacophore whose effect could be strengthened by making adjustments to the
molecular structure, such as in the development of lead molecule libraries.
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Chapter 4
Mass Transport in Arteries with Compromised Elastic
Fibers1
4.1 Introduction
Targeted pharmacological intervention of vascular disease is an increasing area of research for
the treatment of localized defects. The prevention of restenosis following the stenting of
occluded arteries in coronary artery disease through the use of drug-eluting stents has proven
efficacious (1-3) and similar drug eluting stent strategies are being considered for treating
atherosclerotic peripheral arteries. Drug delivery strategies are in development to prevent
neointimal hyperplasia following arterial reconstruction, grafting, and endarterectomy of the
aorta and common carotids (4, 5). Pharmacological management of aortic aneurysms has shown
promise in animal studies (6-9) but has been inconsistent clinically (10, 11) and now targeted
delivery of these drugs is being considered (12-16). With this increasing focus on localized drug
delivery to arterial tissues, the pharmokinetics of these tissues is of interest to better understand
the physical forces that regulate the delivery and retention of the therapeutic agent within the
targeted area (17). In part this includes characterization of the transport properties of arterial
tissue and how these properties are affected by structure and composition of the arterial wall.
1 Reprinted with additional changes from Cocciolone AJ, Johnson E, Shao JY, Wagenseil JE. Elastic fiber
fragmentation increases transmural hydraulic conductance and solute transport in mouse arteries. J Biomech Eng.
2018 Dec 5 with permission from ASME © 2019.
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The wall of large elastic arteries is composed of three layers: intima, media, and adventitia. The
intima is a single layer of endothelial cells that is directly adjacent to the lumen. The media is the
middle layer and makes up the majority of the tissue in the arterial wall. The media is further
sub-layered into concentric layers composed of vascular smooth muscle cells (VSMCs) and an
extracellular matrix (ECM) rich in collagen and elastic fibers. These sub-layers are defined by
dense sheets of elastic fibers called elastic lamellae that appear as concentric formations in the
arterial wall. The outermost layer is the adventitia, composed of fibroblasts and a loose collagen-
rich ECM (18-20).
The endothelial cell layer of the intima is regarded as the most important barrier to the transport
of biological macromolecules and drugs supplied from blood in the lumen to reaching the
innermost layers of the arterial wall (21-25). Less attention has been given to mass transport
beyond the intima. Many transport models and experiments tend to assume the media to be
homogenous and the VSMCs to be the main obstacle to solute transport (23, 25-28). The large
ECM component of the media and its unique layered structure attributed to the elastic lamellae
are not appreciably considered by these models. Several numerical investigations account for
ECM in arterial wall transport and provide evidence that ECM structure and composition are
important contributors toward media layer effective porosity (25, 29). Hwang et al. observed
anisotropic mass transport in bovine carotid tissue with diffusion in the circumferential direction
being greater than diffusion in the transmural direction (30) and they proposed this may be a
result of the non-homogenous arrangement of the elastic fiber network.
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These previous studies provide evidence of ECM contribution to transport within the arterial
wall but none of them are able to isolate the role of individual ECM constituents. Due to its
abundance in the wall and its concentric layering as thick sheets within the arterial media, we
suspect that elastic fibers play a crucial role in limiting solute transport across the wall. To
evaluate the role of elastic fibers in arterial wall transport, we performed transport studies in
fibulin-5 null (Fbln5-/-) mice. Fibulin-5 has the critical role in elastic fiber assembly of regulating
and directing tropoelastin, the monomeric precursor to mature polymeric elastic fibers. The
elastic lamellae of Fbln5-/- arteries are fragmented and improperly organized (30, 31) and we
hypothesized that Fbln5-/- arteries have reduced resistance to transmural transport. We measured
fluid and solute transport in Fbln5+/+ and Fbln5-/- carotid arteries and observed an increase in the
hydraulic conductance and solute flux in the elastic fiber compromised tissue. Additionally, we
supplemented our findings from Fbln5-/- tissue by measuring transport across Fbln5+/+ tissues
following exposure to elastase, an enzyme with high affinity for digesting elastic fibers, and
found similar results.
4.2 Methods
4.2.1 Transport theory
Here we have approximated the arterial wall tissue to be a porous membrane with a homogenous
distribution of uniformly shaped, cylindrical pores. Movement of solute molecules across any
porous membrane occurs through a combination of diffusive and advective (bulk flow) transport
mechanisms. In a sieving membrane, solvent molecules pass unhindered across the membrane
while the solute molecules experience some degree of difficulty in transport. Steric exclusion
based on the size of the solute and pore contributes to preventing the solute from entering the
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membrane. Additionally, the traveling velocity of the solute within the pore may be reduced by
hydrodynamic interaction between the pore wall and the solute.
The differential form of the advection-diffusion equation for one-dimensional, steady-state solute
transport is the following;
 1s v s dcJ J c D dx   (4.1)
where sJ is the net solute flux across the membrane, vJ is the volumetric fluid flux, sD is an
effective diffusivity coefficient of the solute within the membrane, c is the solute concentration
in the membrane at some distance x , and  is the osmotic reflective coefficient which is used
to express the fraction of molecules that are
reflected back instead of entering the
membrane (32).
Theoretical expressions for  are available
that depend on solute radius, a , and effective
membrane pore radius, r . For a membrane
with uniform, cylindrical pores and a solute
approximated as a hard sphere the following
expression for  is used (33, 34);
 21 K   (4.2)
 2partition coefficient 1K    (4.3)
a
r
  (4.4)
Figure 4.1 - Quasi-elastic light scattering data for
FITC-dextran particle radius taken from
Armstrong et al. (35) and fit to a power law
equation.
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Solute hydrodynamic radius can used as an approximation for a . A power law equation for the
dependence of dextran hydrodynamic radius on molecular weight, wM , was fit (R2 = 0.988)
from quasi-elastic light scattering experiment data by Armstrong et al. (Figure 4.1) (35).
0.4890.738 wa M  (4.5)
An expression for vJ can be derived from D’Arcy’s law;
f
v
m
Q dP dcJ RT
A dx dx



     

(4.6)
where fQ is the volumetric flowrate, mA is the cross-sectional area of the membrane normal to
the flow,  is the intrinsic permeability,  is the dynamic fluid viscosity, P is the hydrostatic
pressure, R is the gas constant, and T is the temperature.
Equations 4.1 and 4.6 were derived by Kedem and Katchalsky (32) to describe solute transport
of a neutral solute across a thin, homogenous porous membrane permeable to both solute and
solvent. Integration of equation 4.1 across the thickness of the membrane yields;
   1 ss v DJ J g c c
x
     (4.7)
where  g c is a function of solute concentration across the membrane. Likewise, integration of
equation 4.6 yields;
 v pJ L P RT c    (4.8)
where PL is the hydraulic conductance, an intrinsic property that describes how easily water can
move across the membrane.
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pL
x


  (4.9)
pL can be determined experimentally by measuring the volumetric fluid flux across a membrane
at steady-state, constant pressure, and in absence of a solute concentration gradient. In which
case equation 4.8 can be reduced and rearranged to;
v
p
JL
P
  (4.10)
If advective mediated solute transport is exceedingly larger than diffusive transport, diffusion
can be dropped from equation 4.7 yielding the following reduced equation for sJ where  g c is
simply equal to the solute concentration in the lumen, LC (36).
 1s v LJ J C   (4.11)
4.2.2 Animal tissue preparation
Intact common carotid arteries were removed from four month old (± 14 days) Fbln5+/+ and
Fbln5-/- mice (37) euthanized by carbon dioxide inhalation in compliance with the Institutional
Animal Care and Use Committee. The tissue was stored at 4°C in phosphate-buffered saline
(PBS) until testing which generally occurred within three days of dissection. Overall 92 mice
were used in this study. Structural and mechanical properties of Fbln5+/+ and Fbln5-/- carotids
were investigated by Ferruzzi et al. and determined to be gender independent (38). As a result,
samples from this study were not separated by gender.
4.2.3 Experimental setup
Mass transport experiments were conducted ex vivo using a pressure myograph testing system
and the corresponding software (Danish Myotechnology). For each experiment, the ends of the
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carotid were cannulated and gently secured in-place using 7-0 suture and placed in a 10 mL PBS
bath maintained at 37°C. The carotid was then stretched to a stretch ratio of 1.4, which is the
average in vivo stretch ratio for a mouse carotid artery (39). Denudation of the endothelium was
achieved by bubbling 20 mL of air through the lumen at a constant rate (40). During this step, the
integrity of the artery was confirmed by clamping the outlet tubing and pressurizing the carotid
with air to 100 mmHg. Air escaping from the lumen to the bath indicated a hole in the tissue and
the experiment was not performed. Intact carotids were then pressurized to a hydrostatic pressure
of 100 mmHg using a fluid column attached to the myograph inlet and clamping the tubing at the
myograph outlet. One of three experimental procedures was performed for the measurement of
volumetric fluid flux, net solute flux, or solute uptake into the media. These experiments were
performed on carotids from Fbln5+/+ and Fbln5-/- mice as well as carotids from Fbln5+/+ mice
after an elastase treatment.
4.2.4 Elastase treatment
After mounting and stretching the carotid but before inflation with the hydrostatic pressure
column, Fbln5+/+ carotids were subjected to an elastase treatment. 7.5 units/mL elastase (Elastin
Products Company, EC134) was introduced into the lumen of the artery by a syringe through the
inlet tubing. The outlet tubing was clamped and the artery was pressurized and held at 100
mmHg by further depressing the syringe. After 30 seconds, elastase activity was inhibited by
submerging the mounted carotid in a bath containing a stop solution of 100 mM NaCl PBS (41)
and the lumen of the carotid was flushed with the same solution. The carotid was pressurized to
100 mmHg and was maintained submerged in stop solution for 30 minutes. The lumen was then
flushed with regular PBS and the bath was replaced with 10 mL of fresh PBS and the carotid was
ready for experimentation. Effectiveness of the elastase treatment and subsequent inhibition was
85
verified in a pilot study by tracking post-treatment diameter of the carotid. Uninhibited elastase-
treated carotids continued to increase in diameter during the one-hour observation period while
the inhibited elastase-treated carotids held a constant diameter (Figure 4.2). An increase of
15.6% (± 5.6%) in outer diameter was observed in the elastase-treated carotids used in this study.
Figure 4.2 - Preliminary investigation in developing
and elastase treatment for the arterial tissue. Elastase
activity was inhibited through a high salt buffer
solution. Two-way ANOVA indicated significance (p
< 0.0001) between groups in both time and treatment
conditions. Bonferroni’s multiple comparison test
indicated significance (p < 0.0001) in the comparisons
between uninhibited elastase treated (*) and salt-
inhibited elastase treated (#) to the group untreated
with elastase. Within the elastase treated groups,
significant (p < 0.0001) differences were found
between uninhibited and salt-inhibited groups (†).
4.2.5 Hydraulic conductance
A modification was made to the experimental setup to include a length of tubing between the
myograph inlet and the pressure fluid column. Using a syringe and three-way stopcock, an air
bubble was added to this tubing. After preparing the artery for testing, displacement of the
bubble was measured by taking an image every two minutes for 60 minutes. By continuity, the
volumetric flowrate of the fluid in the tubing is equivalent to the transmural volumetric flowrate
across the arterial wall leading to the following relation,
A T
A T
dx dxQ A V A A
dt dt
      (4.12)
where Q is the fluid volumetric flowrate, A is the cross-sectional area normal to flow and V is
the mean fluid velocity for the artery (A) and tubing (T). Equation 4.12 can be rearranged to
express the transmural fluid flux across the artery ( vJ ) and expanding the area in terms of
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diameter and suture-to-suture length for the artery and inner diameter of the tubing ( Ad , ,A Sl and
Td respectively).
2
,
4
bubble
T
v
A A A S
xdQ tJ
A d l
     (4.13)
At steady-state the volumetric fluid flux can be determined from the slope of displacement
versus time curve for the air bubble and equation 4.13. Further, hydraulic conductance can be
calculated using this fluid flux and equation 4.10 in the solute-free case where the reflection
coefficient is zero.
4.2.6 Solute flux
Net solute transport was assessed by adding 2.5 mg/mL of 4, 70, or 150 kDa FITC-dextran
(Sigma-Aldrich Co.; #46944, #46946, and #46946 respectively) to the fluid column such that the
lumen of the carotid contained a molar concentration of 625, 35.7, or 16.7 µM FITC-dextran,
respectively. Transmural solute transport was monitored over 60 minutes by sampling 50 µl from
the fluid bath outside of the artery twice every 10 minutes after mixing. Concentration was
determined fluorometrically (480 nm excitation, 525 nm emission) against a serial dilution of the
2.5 mg/mL stock solution using a plate reader (Molecular Devices, SpectraMax M2e). Net solute
flux, sJ , was calculated by the following equation,
1 bath
s
A
cJ
A t
   (4.14)
where bathc
t

 is the slope of the bath concentration versus time curve at steady-state.
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4.2.7 Solute uptake
Similarly to the solute flux experiments, 2.5 mg/mL of 4, 70, or 150 kDa FITC-dextran was
added to the fluid column. Transmural advective transport persisted for 30, 60, 120, or 240
minutes in the 4 kDa and 70 kDa experiments but only the 60 minute time point was taken for
the 150 kDa experiments. Post experiment, the arterial lumen was flushed with solute-free PBS.
The artery was removed from the myograph by cutting each end at the tip of the cannulae. A
lateral cut was made the length of the artery to expose the lumen to facilitate the elution of FITC-
dextran from the tissue. A series of elutions was performed by placing the artery in a vial
containing 120 µl of PBS and placing the vial on a shaker at 300 rpm and 37°C, transferring the
tissue to a fresh vial every 24 hours.  In total the artery underwent three elutions and the
fluorescence of each elutant was measured and compared to a standard curve generated from a
serial dilution of stock 2.5 mg/mL FITC-dextran that had undergone the same conditioning as the
samples. Typically 80% of the eluted FITC-dextran appeared in the first elution and the final
elution contained less than 5% of the sum between the three elutions providing confidence that
the majority of FITC-dextran taken up by the artery during the experiment had been eluted. The
values reported are not a true concentration since arterial wall thickness was not measured,
however it has been previously determined that wall thickness is similar between Fbln5+/+ and
Fbln5-/- arteries (31, 39). Therefore, solute uptake is reported here as the total number of moles
of FITC-dextran taken up by the wall normalized to the artery length in the experiment (i.e. μmol
FITC-dextran∙mm-1).
4.2.8 Elastin histology by VVG of carotid cross sections
Four each of Fbln5+/+, Fbln5-/-, and elastase-treated Fbln5+/+ carotids were fixed in 10%
formaldehyde for 24 hours followed by dehydration in ethanol. The samples were paraffin
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embedded and sectioned at the Musculoskeletal Histology and Morphometry Core at the
Washington University School of Medicine. Verhoeff Van Gieson (VVG) stain was used for
visualization of the elastic fiber network structure within the cross section of the carotid wall.
Qualitative assessment of the integrity of the elastic lamellae was compared across the three
groups.
4.2.9 Two-photon microscopy of elastin auto fluorescence in en face carotids
Immediately following dissection and elastase treatment, if required, four each of Fbln5+/+,
Fbln5-/-, and elastase-treated Fbln5+/+ carotids were fixed for one hour in 4% paraformaldehyde
at 4°C. En face slides were prepared by performing a lateral cut the length of the artery and
mounting the tissue on the slide such that the lumen faced upward and in direct contact with the
coverslip. Imaging was performed by the Washington University Center for Cellular Imaging
(WUCCI) at the Washington University School of Medicine using a Zeiss LSM 880 Airyscan
two-photon microscope and a 40x/1.2 silicon immersion objective. A z-stack of elastin auto
fluorescence was captured at 330 nm increments across the thickness of the arterial wall by using
a 488 nm laser for excitation and collecting the emission signal between 500 and 550 nm (42,
43). Deconvolution of the z-stacks was performed using the software, Autoquant.
4.2.10 Statistical analysis
Comparisons were made between tissue types at the same FITC-dextran size or time point. All
statistics were performed using GraphPad Prism software with significance considered at P <
0.05. All comparisons were performed by a one-way ANOVA and Tukey’s post hoc. Statistical
significance between Fbln5+/+ and Fbln5-/- (*), Fbln5+/+ and elastase-treated Fbln5+/+ (†), and
Fbln5+/+ and elastase-treated Fbln5+/+ (#) samples are indicated on the figures.
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4.3 Results
4.3.1 Elastin histology shows compromised elastic fibers
Representative VVG stains of Fbln5+/+, Fbln5-/-, and elastase-treated Fbln5+/+ carotid cross-
sections are presented in Figure 4.3. The elastic lamellae (stained in black) from the Fbln5+/+
(1A) appear as smooth, continuous layers within the media. In contrast, the continuity of the
elastic lamellae in the Fbln5-/- tissue (1B) is disrupted by over-deposition of elastin in some areas
and under-deposition in others lending to an overall fragmented appearance. These histological
images are in agreement with previously published results (30, 31, 37). The elastase-treated
Fbln5+/+ carotid (1C) retains the continuity of the elastic lamellae and the elastic lamellae appear
to be thinner than in untreated Fbln5+/+. The elastase treatment used in this study was intended to
reduce the transport resistance of the elastic lamellae but to avoid complete removal of the elastic
fibers and the histology images indicate that the elastic lamellae are still intact. The surrounding
VSMC’s appear more loosely arranged than in the Fbln5+/+ tissue, possibly due to the removal of
the thin elastic fibers in the muscle tissue regions between elastic lamellae.
Figure 4.3 - Representative histological cross-sections of Fbln5+/+ (A), Fbln5-/- (B), and elastase-treated
Fbln5+/+ (C) carotid arteries. The elastic lamellae are colored black by the VVG stain. The arterial lumen (L)
is towards the bottom of the images. Phenotypic over-deposition and under-deposition of elastin within the
elastic lamellae of Fbln5-/- are indicated by blue, upward-facing arrows and green, downward-facing arrows
respectively. The scale bar indicates 20 µm.
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4.3.2 Elastin auto fluorescence reveals changes in elastic fiber density
Representative en face images from the two-photon microscopy of elastin auto fluorescence from
Fbln5+/+, Fbln5-/-, and elastase-treated Fbln5+/+ carotids are shown in Figure 4.4. A single plane
of the en face z-stack and the orthogonal views are shown to visualize the elastic fiber network in
three-dimensions. The elastic lamellae undulate in-and-out of the en face image plane as a result
of their characteristic wavy pattern, which is evident from the orthogonal views and the
histological cross-sections in Figure 4.3. The over- and under-deposition of elastin within the
lamellae of Fbln5-/- arteries is evident in the en face images and is consistent with the
histological images. Changes in the density and arrangement of the elastic fibers may increase
the effective porosity of the Fbln5-/- elastic lamellae and contribute to the observed increase in
solute transport. Fenestrations (holes) in the elastic lamellae are visible in the higher
magnification en face images and appear similar in all three groups. There is no apparent
difference in elastic fiber density or organization due to the elastase treatment, indicating the
subtle nature of the treatment protocol. Additional more quantitative investigation is required to
identify structural changes in the elastase treated group that may contribute to the observed
differences in transport properties.
4.3.3 Hydraulic conductance is influenced by elastic fiber integrity
Steady-state volumetric fluid flux was achieved rapidly after the start of the experiment,
evidenced by the linear displacement curves of the tracking bubble (Figure 4.5A, R2 > 0.99 in all
experiments). The slope of the displacement curve was used in Eq. (8) to determine volumetric
fluid flux, which was then used with Eq. (6) to calculate the intrinsic hydraulic conductance for
each group (Figure 4.5B). The elastic fiber compromised tissue of the Fbln5-/- and elastase-
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treated Fbln5+/+ carotids resulted in a 6 and 7-fold increase in hydraulic conductance,
respectively, compared to Fbln5+/+ tissue.
Figure 4.4 - Representative two-photon microscopy images of elastin auto fluorescence from en face Fbln5+/+
(A and D), Fbln5-/- (B and E), and elastase-treated Fbln5+/+ (C and F) carotids. Panels A, B, and C are views of
a single plane from the z-stack within the internal elastic lamella. Orthogonal views of the z-stack are shown
next to Panels A, B, and C for three-dimensional visualization. The orientation for each image is indicated
(circ = circumferential, long = longitudinal, rad = radial). The yellow lines represent the image location within
the z-stack. The red scale bar indicates 50 µm. Panels D, E, and F are magnified z-projections of four
consecutive planes from the z-stack within the internal elastic lamella. Blue, upward facing arrows indicate a
fenestration (hole) within the elastic lamina. Green, downward facing arrows show the elastic lamella
undulating out of the z-projection plane. The yellow scale bar indicates 10 µm.
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4.3.4 Total solute flux reveals size exclusion properties
It is apparent by the constant rate of change in FITC-dextran concentration in the external bath
that the solute transport across the arterial wall reached steady-state in less than 10 minutes of
experimentation for all tested FITC-dextran sizes (Figures 4.6A-C, R2 > 0.98 in all experiments).
The slope of the bath concentration versus time curves and Eq. (9) was used to determine the net
solute flux across the wall (Figure 4.6D). Fbln5-/- carotids have a 4-fold increase in 4 kDa FITC-
dextran solute flux compared to Fbln5+/+ carotids. The change in solute flux is more drastic in
the case of 70 kDa, having a 22-fold increase in Fbln5-/- compared to Fbln5+/+. However, in the
case of 150 kDa the difference drops to a 3-fold increase. Overall, the Fbln5-/- tissue exhibits a
linear decrease in solute flux with increasing dextran size on the semi-log scale (Figure 4.6D)
Figure 4.5 - Results from the volumetric
fluid flux experiments. Panel A – The
displacement of the tracking bubble over
time for each of the tissues. Error bars
are SEM for clarity. Panel B –
Hydraulic conductance of Fbln5+/+ (n =
7), Fbln5-/- (n = 8), and elastase-treated
Fbln5+/+ carotids (n = 8). Error bars are
SD. Statistical significance was
determined between Fbln5+/+ and Fbln5-
/- (* p = 0.0021) and between Fbln5+/+
and elastase-treated Fbln5+/+ († p =
0.0004).
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while the Fbln5+/+ tissue experiences a sharper decrease in solute flux from 4 to 70 kDa but a
minimal change in solute flux from 70 to 150 kDa. This indicates a shift in the size exclusion
limit between the tissues as a result of the elastic fiber fragmentation in the Fbln5-/- tissue.
Elastase-treated Fbln5+/+ carotids have a 4 kDa solute flux that is not significantly different from
untreated tissue (Figure 4.6D). There is a significant increase in 70 kDa solute flux and it is
comparable in magnitude to the increase demonstrated by Fbln5-/- carotids over untreated
Fbln5+/+ carotids at the same dextran size. The 150 kDa solute flux in elastase-treated Fbln5+/+
carotids is significantly increased 13-fold and 4-fold over Fbln5+/+ and Fbln5-/- carotids,
respectively. The net solute flux of FITC-dextran across elastase-treated tissue is independent of
dextran size, suggesting that the relative pore size is increased sufficiently that the tissue no
Figure 4.6 - Results from the net solute flux experiments. The
change in solute concentration in the external bath with time
for the 4, 70, and 150 kDa FITC-dextrans are shown in panels
A, B, and C respectively (n = 5-9). Error bars are SEM for
clarity. Panel D – The net solute flux across the carotid wall of
the investigated dextran sizes on a semi-log plot. Statistical
significance between Fbln5+/+ and Fbln5-/- (*), Fbln5+/+ and
elastase-treated Fbln5+/+ (†), and Fbln5+/+ and elastase-treated
Fbln5+/+ (#) are indicated. Error bars are SD.
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longer has sieving capability at the tested FITC-dextran sizes. The results for the elastase-treated
tissue provide additional evidence that changes to the elastic fiber network structure will alter
solute transport. Based on the differences in behavior between the groups for different FITC-
dextran sizes, it appears that alterations in solute transport depend on the mechanisms leading to
elastic fiber defects (i.e. genetic disruptions in elastic fiber assembly versus protease digestion of
mature elastic fibers).
4.3.5 Solute uptake is variably affected by elastic fiber disruption treatment
Dextran uptake concentration was decreased in the Fbln5-/- tissue compared to Fbln5+/+ for 4 and
70 kDa FITC-dextran at every time point tested (Figure 4.7A and 4.7B respectively). In these
time course experiments there was a steady increase in solute uptake over time. This may be a
result of passive diffusion of solute into void spaces within the tissue that are not accessible to
the transmural fluid flux.
4 kDa FITC-dextran concentration (Figure 4.7A) was increased in both Fbln5+/+ and Fbln5-/-
carotids compared to 70 kDa FITC-dextran (Figure 4.7B) at all time points and is likely a result
of a combination of factors including the larger molar concentration and smaller solute size of 4
kDa FITC-dextran.
Solute uptake for 150 kDa FITC-dextran was measured only after 60 minutes. A comparison of
solute uptake for each dextran size at 60 minutes is presented in Figure 4.7C. Interestingly, the
significant decrease in solute uptake by Fbln5-/- carotids in the 4 and 70 kDa studies is lost in the
150 kDa study. This indicates that 150 kDa FITC-dextran is large enough to minimize any
impact of the differences in porosity between the Fbln5+/+ and Fbln5-/- tissues
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Additionally, solute uptake at each dextran size was measured after 60 minutes for elastase-
treated Fbln5+/+ arteries. The results are included in Figure 4.7C. At the 4kDa FITC-dextran size,
there is a decrease in solute uptake for elastase-treated Fbln5+/+ arteries, comparable to that
observed in the Fbln5-/- tissues. At 70 kDa the behavior between these groups diverge as the
elastase-treated tissue now has increased solute uptake compared to untreated tissue. The same
trend is observed at 150kDa FITC-dextran. Overall, the trend of reduced solute uptake observed
with dextran size in Fbln5+/+ and Fbln5-/- tissues is diminished in the elastase-treated tissues.
Figure 4.7 - Results from the solute uptake
experiments. Quantity of 4 kDa (A) and 70 kDa (B)
FITC-dextran retained within the wall of the Fbln5+/+
and Fbln5-/- carotids after 30, 60, 120, and 240
minutes (n = 6-7). The value is normalized to the
length of the artery. Statistical significance between
Fbln5+/+ and Fbln5-/- (*) was determined at the
indicated dextran size and time. Error bars are SEM
for clarity. Panel C – Isolated results at 60 minutes
including 150 kDa FITC-dextran and elastase-treated
artery experiments. Statistical significance between
Fbln5+/+ and Fbln5-/- (*), Fbln5+/+ and elastase-treated
Fbln5+/+ (†), and Fbln5-/- and elastase-treated Fbln5+/+
(#) are indicated. Error bars are SD.
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4.3.6 Change to effective pore radius is not adequate to describe results
The mass transport parameters measured in this investigate enable the use of porous membrane
mass transport theory to make predictions on the structural changes in the Fbln5-/- and elastase
treated Fbln5+/+ arteries that are responsible for the observed results. Darcy’s law for fluid
transport (equation 4.8) and the expression for advection dominated solute mass transport
(equation 4.11) can be used in conjunction to determine the reflection coefficient,  for each
tissue and FITC-dextran size (Figure 4.8A). Subsequently, the expressions in equations 4.2, 4.3,
and 4.4 for steric-based determination of  , along with equation 4.5 for empirical determination
of FITC-dextran particle radius can be used to estimate effective pore radius of the tissues
(Figure 4.8B). Standard deviation for  was determined by propagation of standard deviation
assuming simple division of the experimentally determined parameters pL and sJ .
An apparent trend in the results is an increase in effective pore radius with FITC-dextran size in
all tissues. Since pore size should remain constant at static mechanical circumferential and axial
deformation of the arterial tissue, this result suggests that the assumption of uniform,
homogeneous pore network structure is inappropriate, despite its wide use in tissue transport. It
is likely that there is a tissue specific distribution of pore size and shape, so that using the current
equations will over-estimate the effective pore radius when larger solutes are used since smaller
pores are effectively impermissible. The reciprocal is also true. Smaller solute molecules
entering a large pore would be indistinguishable from solute entering many smaller pores
equaling the pore area of the single larger pore. Additionally, the alterations to fluid and solute
transport in elastic fiber compromised tissue that we demonstrate in this investigation inherently
violate the assumption of a homogenous porous membrane since the elastic fiber network
structure is markedly inhomogeneous. This theoretical investigation of effective pore radius
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provides evidence that the currently used transport theory may inadequately describe the mass
transport properties across the arterial wall and more comprehensive numerical models must be
used.
Figure 4.8 – Theoretical reflection coefficient (A) and tissue effective pore radius (B) for the carotid tissues
and FITC-dextran molecules utilized in this study.
4.4 Discussion
To the best of our knowledge this is the first empirical investigation of mass transport in the
medial layer of arterial tissue in which the elastic fiber network has been specifically
compromised. We have continued the assumptions made in other investigations that the media
behaves as a homogenous, porous membrane to simplify experimentation and numerical
analyses. Our investigation isolates the role of the elastic fiber network on the intrinsic transport
properties of the arterial wall by comparing mass transport in wild type mouse common carotids
to those with genetically and enzymatically compromised elastic fiber integrity. While our
investigation is focused on the elastic fibers, there are additional ECM components in the wall,
including collagen fibers and proteoglycans, which may also influence arterial wall transport.
Our observations of increased volumetric fluid flux and net solute flux in elastic fiber
compromised tissues provide evidence that the ECM should not be overlooked in theoretical or
experimental studies of arterial wall mass transport.
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The hydrodynamic radius of 4, 70, and 150 kDa FITC-dextran is approximately 1.5, 5.9, and 8.6
nm, respectively (35). These sizes are several orders of magnitude smaller than the radius (0.5 –
5 μm) of the fenestrae that are characteristic of the morphology of elastic lamellae within the
arterial wall (44, 45) and can be observed in the two-photon microscopy images presented in
Figure 2. The fenestrations implicitly contribute to the transmural hydraulic conductance of the
arterial wall. However, their relatively large size suggests they are not a factor towards the
resistance of solute transport of the dextran molecules used in this study. Increased size and
frequency of fenestrations within the aorta has been observed in a mouse model of Marfan
syndrome, an autosomal dominant genetic disorder having numerous connective tissue defects
including elastic fiber fragmentation and dilation of the aorta (44). Although the size and density
of elastic lamellae fenestrations were not qualitatively different between groups in our study,
additional, quantitative analyses may highlight subtle differences that should be considered for
transport of targeted pharmacologic therapies in elastic fiber related diseases, such as Marfan
Syndrome.
The effective radius of the pores passing between the elastic fibers within the elastic lamellae of
wild-type arteries can be approximated to be between the hydrodynamic radii of 4 and 70 kDa
FITC-dextran, based on the size exclusion behavior observed in Figure 4D. This size exclusion
behavior is diminished in the Fbln5-/- artery, indicating a change in the effective pore radius of
the genetic mutant and is likely a result of the apparent change in the density and arrangement of
the elastic fibers within the elastic lamellae, as indicated in the two-photon microscopy images.
The elastase-treated wild-type arteries allowed all sizes of FITC-dextran particles through at
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approximately the same rate. The size range at which these solute exclusion behaviors occur, or
the absence of size exclusion behaviors, has important physiological implications on which
biomolecules can more readily transverse the arterial wall. Cofactors and small molecule
pharmaceuticals are generally smaller than 1 kDa and therefore may experience low resistance to
transport by the elastic lamellae in wild-type arteries. Biologics and growth factors which can
span 10 – 100 kDa in size are likely impacted by the filtration effect of the elastic lamellae in
wild-type arteries, but would more easily transverse the wall of arteries with genetic or
enzymatic defects in the elastic lamellae. The elastic lamellae in wild-type arteries may be
impermeable to much larger macromolecules such as members of the low-density lipoprotein
family, which have significant contribution to the onset and progression of atherosclerosis, but
may be permeable to these molecules when the elastic lamellae are enzymatically compromised.
Removal of the intimal layer of endothelial cells prior to experimentation allowed more direct
measurement of medial layer transport properties, which has a prominent ECM component. The
effect of stripping the endothelial layer on the hydraulic conductance of large elastic arteries has
been studied previously by other investigators in order to isolate the medial layer contribution to
transport. A denuded artery has a hydraulic conductance of nearly twice that of an intact vessel
(46-48). Our investigation further advances the knowledge of how arterial wall structural
features contribute to advective transport resistance by demonstrating a 6-fold and 7-fold
increase in hydraulic conductance in Fbln5-/- and elastase-treated Fbln5+/+ carotids, respectively,
compared to untreated Fbln5+/+. This increase in hydraulic conductance in the medial layer of
elastic fiber compromised artery is strong evidence that the elastic fiber network contributes to
the resistance of flow across the arterial wall.
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Our investigation appears to be the first to report hydraulic conductance for mouse arterial tissue.
Our wild-type arterial hydraulic conductance for the denuded mouse carotid is 49.9·10-8 cm∙s-
1∙mmHg-1 which is 5 to 40 times greater than values reported from studies involving arteries
from other organisms. Performing transport experiments on mouse carotids is challenging owing
to their small size. As such, the possibility that our results are overestimated due to an unforeseen
technical limitation cannot be dismissed. However, there are several physiological differences in
the elastic fiber network of mouse carotids compared to the arteries tested by other investigators
that could account for this difference. The number of elastic lamellae tends to increase across
animal species when ordered by animal size (49). Additionally, the number of elastic lamellae
within the media decreases along the arterial tree. We surmise these characteristics of the elastic
fiber network structure could account for the differences. Hwang et al. observed differences in
transport properties of arteries from different locations in the arterial tree (50). Shou et al.
reported a hydraulic conductance of 4.89·10-8 cm∙s-1∙mmHg-1 at 100 mmHg for denuded rat aorta
(8 lamellae) which has several more elastic lamellae than our mouse carotid (4 lamellae) (49),
however one caveat is that they did not apply an axial stretch to bring the artery to a
physiological conformation for experimentation (48). For the denuded rabbit aorta (~22 elastic
lamellae), Tedgui and Lever report a hydraulic conductance at 180 mmHg of 5.27·10-8 cm∙s-
1∙mmHg-1 (46) and Baldwin et al. report a value of 3.5·10-8 cm∙s-1∙mmHg-1 in one investigation
(51) and 10.0·10-8 cm∙s-1∙mmHg-1 in another investigation at 100 mmHg (47). Tarbell et al.
reported a value for the denuded rabbit carotid of 1.25·10-8 cm∙s-1∙mmHg-1 at 100mHg which has
~6 more elastic lamellae than the mouse carotid (52-54).
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While there is no clear trend in hydraulic conductance with number of elastic lamellae from
these literature values, the results from our study suggest the architecture of the elastic fiber
network should be a determining factor. We propose that the hydraulic resistance of the arterial
media is equivalent to the sum of the hydraulic resistances of each individual lamellae. Our
hypothesis is only applicable if the elastic fiber component of the wall has a prominent effect on
transport since without elastic fibers the wall would more closely resemble a homogenous tissue
of VSMCs and other ECM constituents. Future investigation is needed to determine whether a
relationship exists between hydraulic resistance and number of elastic lamellae. If such a relation
exists then it would be beneficial knowledge towards the design of drug delivery strategies. The
drug concentration loaded onto the delivery platform may be adjusted according to the elastic
fiber network structure of the targeted artery to improve the therapeutic response.
Elastic and collagen fiber arrangement and structure in the arterial wall are affected by
physiological mechanical loading. Circumferential strain applied by increases in blood pressure
results in the rearrangement and straightening of these ECM components (55, 56). Previous
investigations indicate a dependence of arterial hydraulic conductance changes on the pressure
gradient across the wall (47, 48, 51). By our findings it is reasonable to suggest that
rearrangement of the ECM in response to changes in pressure is one of the mechanisms
responsible for this dependence. The large arteries experience dynamic changes in acting forces,
implicating that the intrinsic transport properties may be more dynamic than what is typically
assumed.
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Aortic aneurysms have severe structural defects in the arterial wall ECM microstructure
including fragmentation and degradation of the elastic lamellae. The results from our study
suggest that aneurysmal tissue could have increased hydraulic conductivity and effective
porosity compared to surrounding healthy arterial tissue. One therapeutic strategy may be to
design anti-inflammatory drug delivery systems which take advantage of this difference in
transport properties. A delivery vehicle small enough to enter into the aneurysmal tissue from the
arterial lumen but too large to diffuse to surrounding healthier tissue may effectively concentrate
the drug to the diseased area.
Accumulation of defects to the elastic fiber network of arterial tissues is observed in aging and
disease progression. Elastic fiber degradation is a factor in numerous cardiovascular diseases
including hypertension, aneurysm development, and arterial calcification (57-60). Reduced
elastic fiber crosslinking, increased elastolytic activity, and higher elastic fiber fragmentation has
been observed in mouse models of obesity (61). Elastic fiber fragmentation may be involved in
both the initiation of plaque development in atherosclerosis (62) and exacerbation of the disease
(63-65). In aging, elastic fiber composition in the large conduit arteries drops over the human
lifespan (60, 66) but this is likely an effect of disproportionate increases of other ECM
constituents in the wall while changes to elastic fiber quantity is nominal (67, 68). Elastic fibers
do, however, accumulate damage and defects over time resulting in increased fragmentation with
aging (69), as de novo elastic fiber synthesis or repair is not evident in adult tissues (57). The
cause of fragmentation is not well understood but it is likely that the high number of cardiac
loading cycles over an organism’s lifetime causes mechanical failure in the elastic fiber network
(70) for which there is no known repair mechanism. It is also thought that an imbalance in the
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elastolytic enzymes contributes to elastic fiber degradation (59, 71). The influence on arterial
transport by elastic fiber integrity has important implications on the kinetics of biomolecules
involved in aging and cardiovascular disease, warranting future investigation.
Similar to an aged artery, arteries from Fbln5-/- mice do not demonstrate appreciable changes in
elastic fiber amount although they do not have the same increases in collagen content normally
associated with aged arteries (31, 72). Fragmentation in arterial elastic lamellae of Fbln5-/- mice
is a result of improper elastic fiber assembly in development rather than mechanical fatigue and
there is no evidence of heightened elastolytic activity (30, 31, 37). As such, the disruption to the
elastic fiber network in Fbln5-/- mouse occurs through a different mechanism than the damage
that accumulates in the elastic fibers of aged human arteries. Regardless, in the context of
transport the result is likely similar such that a similar decrease in resistance to advective mass
transport that we report for Fbln5-/- carotids may also occur in aged arteries. Additionally, the
experiments using an elastase treatment for elastic fiber degradation in most cases demonstrate
similar results as the Fbln5-/- experiments providing evidence that elastic fiber degradation,
regardless of the mechanism responsible, can largely impact transport. The degradation of an
individual’s arterial elastic fiber network in aging and disease could impact the transport of
biomolecules and drugs across the arterial wall and has implications for the progression of
vascular disease and efficacy of drug delivery therapies that target the arterial media.
4.5 Conclusions
We have investigated the transport properties of elastic fiber compromised arterial tissue to
evaluate whether changes to the elastic fiber network structure have significant impact on the
transport properties of the arterial wall. It is apparent from our histological cross-section and en
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face two-photon microscopy images that Fbln5-/- carotids have several phenotypic changes to the
structure of the elastic lamellae including a fragmented appearance. We hypothesized that these
structural changes would translate to a increase in tissue porosity and tested this hypothesis with
measures of fluid and solute transport. We observed an increase in hydraulic conductance, net
solute flux, and reduced solute uptake compared to Fbln5+/+ carotids and conclude this to be
strong evidence that the elastic fiber network plays a significant role in determining the transport
properties of the arterial wall. Similar changes in most cases were observed when the elastic fiber
network was exposed to a brief elastase treatment.
From our results, the native elastic fiber network within the arterial media contributes to the
resistance of bulk transport across the arterial media. Elastic fibers predominately form sheet-like
layers within the arterial wall and are partly responsible for the non-homogenous structure of the
media. Previous transport studies have approximated the media to be homogenous and have
largely ignored the elastic fiber component. Our results suggest this may be an oversimplification
that should be addressed in future studies to improve the understanding of transport within
arterial tissue. Fragmentation, rearrangement, and degradation of the elastic fiber network in
disease and aging may have significant impact on the transport of macromolecules within the
arterial wall and could impact effectiveness of drug delivery therapies targeting these tissues.
4.6 Limitations
In this study we made the assumption that diffusive solute transport was insignificant compared
to advective transport. This is supported by several previous numerical and experimental
investigations that have reported high Péclet numbers for small molecules and small proteins in
arterial tissue (17, 29, 73, 74). However, we observed a steady increase in solute uptake within
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the tissue even after 4 hours despite steady-state, transmural advective transport being achieved
in less than 10 minutes. This is possibly a consequence of passive diffusion including diffusion
in directions other than across the wall. This observation indicates that arterial wall transport
from the lumen and across the wall is not sufficiently described in the one-dimensional scenario,
especially since the non-homogenous elastic fiber network has an impact on solute transport.
Three-dimensional diffusion is difficult to measure given the small size of the mouse carotid
tissue, especially if in vivo conformation is to be retained. However, our results provide new
evidence for the contribution of the elastic fiber component to arterial wall transport to better
inform more complex theoretical transport models.
Another limitation to this study is that concentration polarization may be a contributing factor
towards the overall solute transport. Without measurements of changes in FITC-dextran
concentration in the lumen throughout the course of the experiment it is difficult to conclude to
what degree concentration polarization affects the results of this study. However, the constant
rate of solute transport for each FITC-dextran in Figure 4 is evidence against concentration
polarization having a significant affect in this study but may be an important in future studies.
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Chapter 5
Conclusions
The research presented in this thesis has focused on one core motivation – to contribute to an
improved understanding of elastic fiber assembly and degeneration such that intervention for
genetic and acquired elastinopathies may be better designed. While it is clear from our review of
elastic fiber function in physiology and disease in chapter 2 that prior investigations have
contributed substantial knowledge, it is also evident that there is a significant amount of the
elastic fiber assembly and degradation process that is not yet understood. If we are to advance
modern medicine towards the attenuation of elastic fiber degradation in cardiovascular diseases
including hypertension, atherosclerosis, diabetes, obesity, and aneurysm progression there is
more research to be done. We submit that our research presented here has provided small, but
significant advancement to the field.
The first research aim accomplished in this thesis was the development of a platform for
screening molecular factors for an elastic fiber assembly agonist. To do this, we selected an
immortalized cell line, RFL6, that is known to produce elastic fibers in vitro and measured
significant increases in elastic fiber production with in-culture time using a competitive ELISA
for desmosine. We assessed the effect of DMSO concentration on cell protein production in
order to avoid cytotoxic effects from DMSO in future screening endeavors. We demonstrated
utility in our screening platform by observing a reduction in elastic fiber production in cell
treated with ßAPN, an inhibitor of elastic fiber cross-linking. The suitability of growth factors,
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insulin and TGF-ß1, and of antihypertensive drugs, diazoxide, minoxidil, and captopril, to serve
as positive controls of elastic fiber production in our screening platform was investigated but we
determined that none of these factors upregulate elastic fiber assembly in our cell culture
conditions. Finally, we performed a high-throughput screen of the NCI Diversity Set V library of
nearly 1600 small molecules using the platform we developed. While 7 molecules scored as
positive hits in the primary screen, none of them were agonistic to elastic fiber assembly in
subsequent, more robust secondary investigations. Regardless of the lack of success in
identifying a small molecule to upregulate crosslinked elastic fiber production in vitro, the
biochemical assay platform that we optimized has been useful to our lab and collaborations for
determining elastic fiber content in tissues such as the aorta and tendon.
We maintain that our screening platform can be improved with additional development. While
RFL6 cells produce elastic fibers in vitro, their elastic fiber producing capability may be
saturated and they may be unable to be pushed towards increased production.  Investigation into
alternate elastic fiber producing cell types may identify a more suitable option for the screening
platform. The caveat is that many cell types that produce elastic fibers are primary cells from
neonatal animal tissues, which may be too variable in viability and phenotype for large screens,
but may be suitable for smaller scale investigations. Another possibility is that our cells need to
be made more amendable towards elastic fiber production with growth factors like insulin and
TGF-ß1, in addition to the compound of interest. Future elucidation of the elastic fiber assembly
mechanism may also reveal conditions or factors required to promote elastic fiber assembly in
vitro. In the more immediate future, factors that have demonstrated regulation of elastin gene
expression can be investigated for elastic fiber maturation using our platform. The identification
114
of elastic fiber agonists would advance the field of tissue-engineered arteries and pharmaceutical
development for the treatment of elastin-related diseases.
The second aim of this research was to address the hypothesis that elastic fiber network structure
in the extracellular matrix of arterial tissue impedes the transport of fluid and solute across the
arterial wall. To perform this investigation, we adapted mass transport experimental techniques
normally used in larger, undeformed tissues for mouse carotid arteries mechanically loaded to
the physiological axial and circumferential conformation. Using the Fbln5-/- mouse with
disrupted elastic fiber formation and an elastase treatment we developed, we investigated the
effects of compromised elastic fiber integrity on mass transport parameters. From our measures
of increased hydraulic conductance and increased advective solute transport, we concluded that
the elastic fiber component of the arterial wall has significant impact on mass transport. This
discovery is significant because previous investigations have ignored the elastic fiber component
and attributed all of the mass transport properties to the distribution and arrangement of the
vascular smooth muscle cells. With the increasing attention to the development of targeted
pharmaceutical therapies for treating vascular diseases associated with elastinopathies, our
conclusions provide an improved understanding of the pharmokinetics of arterial tissue.
The evidence of elastic fiber contribution to arterial mass transport is only the beginning of this
investigative area. Future investigations are needed to better gauge the impact of elastic fiber
degradation on therapies. The models used here are more extreme, but viable examples of elastic
fiber disruption. Repeated studies in human tissue from individuals having a genetic or acquired
elastinopathy would reveal whether the influence elastic fibers have on transport is significant
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with a pathophysiological range of elastic fiber perturbation. Additionally, technical limitations
have limited our investigation towards advection driven mass transport but diffusive transport
would become more relevant in the study of transport of larger macromolecules. To measure
diffusive properties, larger scale tissues are required and a testing apparatus is needed that can
stretch the tissue to physiological conformation but without a pressure gradient across the tissue.
Finally, our results reveal that the heavily simplified mass transport theory most often used for
arterial tissue is insufficient. Large arteries from humans experience more dynamic physical
forces, have extensive tissue inhomogeneity, and likely have a distribution of effective pore size
and shape. Even more sophisticated, computational models tend to underestimate elastic fiber
contribution and the results from our empirical investigation may help refine these models in the
future.
